Category,Category Name,Data Code,Data Name,Date,Patient Count,Normalized Patient Count
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-04-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-04-2023,116,0.073278585
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-04-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-04-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-04-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-04-2023,20,0.012634239
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-04-2023,18,0.011370815
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-04-2023,18,0.011370815
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-04-2023,48,0.030322173
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-04-2023,32,0.020214782
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-04-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-04-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-04-2023,208,0.131396083
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-04-2023,26,0.01642451
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-04-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-04-2023,208,0.131396083
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-04-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-04-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-04-2023,0,0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-04-2023,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-04-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-04-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-04-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-04-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-04-2023,100,0.523560209
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-04-2023,51,0.267015707
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-04-2023,2,0.010471204
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-04-2023,100,0.523560209
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-04-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-04-2023,0,0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-04-2023,100,0.523560209
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-04-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-04-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-04-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-04-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-04-2023,49,0.453608247
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-04-2023,8,0.030927835
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-04-2023,49,0.453608247
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-04-2023,46,0.240837696
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-04-2023,53,0.277486911
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-04-2023,7,0.036649215
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-04-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-04-2023,99,0.518324607
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-04-2023,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-04-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-04-2023,99,0.518324607
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-04-2023,99,0.518324607
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-04-2023,99,0.518324607
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-04-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-04-2023,50,1
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-04-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-04-2023,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-04-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-04-2023,99,0.475961538
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-04-2023,99,0.475961538
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-04-2023,99,0.475961538
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-04-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-04-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-04-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-04-2023,12,0.031088083
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-04-2023,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-04-2023,10,0.025906736
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-04-2023,4,0.010362694
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-04-2023,10,0.025906736
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-04-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-04-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-04-2023,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-04-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-04-2023,11,0.028497409
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-04-2023,12,0.031088083
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-04-2023,6,0.015544041
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-04-2023,2,0.005181347
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-04-2023,30,0.077720207
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-04-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-04-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-04-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-04-2023,0,0
M8,Family Planning,8.17.1,Complications following male sterilization,01-04-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-04-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-04-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-04-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-04-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-04-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-04-2023,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-04-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-04-2023,99,0.523809524
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-04-2023,99,0.523809524
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-04-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-04-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-04-2023,99,0.523809524
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-04-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-04-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-04-2023,99,0.523809524
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-04-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-04-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-04-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-04-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-04-2023,12,0.063492063
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-04-2023,14,0.074074074
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-04-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-04-2023,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-04-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-04-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-04-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-04-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-04-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-04-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-04-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-04-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-04-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-04-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-04-2023,38,0.322033898
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-04-2023,18,0.152542373
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-04-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-04-2023,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-04-2023,0,0
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-04-2023,47,0.176691729
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-04-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-04-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-04-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-04-2023,43,0.161654135
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-04-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-04-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-04-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-04-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-04-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-04-2023,0,0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-04-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-04-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-04-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-04-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-04-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-04-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-04-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-04-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-04-2023,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-04-2023,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-04-2023,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-04-2023,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-04-2023,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-04-2023,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-04-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-04-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-04-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-04-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-04-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-04-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-04-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-04-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-04-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-04-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-04-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-04-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-04-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-04-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-04-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-04-2023,700,0.018471119
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-04-2023,575,0.015172705
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-04-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-04-2023,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-04-2023,142,0.003746998
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-04-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-04-2023,1149,0.030319023
M14,Patient Services,14.1.8,Outpatient - Dental,01-04-2023,864,0.022798638
M14,Patient Services,14.1.9,Outpatient - ENT ,01-04-2023,721,0.019025253
M14,Patient Services,14.1.10,Outpatients- Asthma,01-04-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-04-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-04-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-04-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-04-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-04-2023,16,0.000422197
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-04-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-04-2023,950,0.025067947
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-04-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-04-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-04-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-04-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-04-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-04-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-04-2023,645,0.017019817
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-04-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-04-2023,15866,0.418661108
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-04-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-04-2023,71,0.001873499
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-04-2023,561,0.014803283
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-04-2023,67,0.00176795
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-04-2023,611,0.016122648
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-04-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-04-2023,102,0.002691506
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-04-2023,481,0.012692298
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-04-2023,95,0.002506795
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-04-2023,564,0.014882445
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-04-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-04-2023,4,0.000105549
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-04-2023,6,0.000158324
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-04-2023,2,5.28E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-04-2023,2,5.28E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-04-2023,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-04-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-04-2023,5,0.000131937
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-04-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-04-2023,2,5.28E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-04-2023,8,0.000211099
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-04-2023,8,0.000211099
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-04-2023,1,2.64E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-04-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-04-2023,34,0.000897169
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-04-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-04-2023,288,0.007599546
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-04-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-04-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-04-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-04-2023,6,0.000158324
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-04-2023,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-04-2023,33,0.000870781
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-04-2023,4,0.000105549
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-04-2023,14,0.000369422
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-04-2023,7,0.000184711
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-04-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-04-2023,75,0.001979048
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-04-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-04-2023,1541,0.040662849
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-04-2023,580,0.015304642
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-04-2023,81,0.002137372
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-04-2023,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-04-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-04-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-04-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-04-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-04-2023,21,0.000554134
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-04-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-04-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-04-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-04-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-04-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-04-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-04-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-04-2023,1,2.64E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-04-2023,450,0.011874291
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-04-2023,24,0.000633296
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-04-2023,274,0.007230124
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-04-2023,5,0.000131937
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-04-2023,25,0.000659683
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-04-2023,2,5.28E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-04-2023,0,0
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-04-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-04-2023,7099,0.187323535
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-04-2023,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-04-2023,0,0
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-04-2023,0,0
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-04-2023,0,0
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-04-2023,0,0
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-04-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-04-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-04-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-04-2023,95,0.002506795
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-04-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-04-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-04-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-04-2023,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-04-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-04-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-04-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-04-2023,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-04-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-04-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-04-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-04-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-04-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-04-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-04-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-04-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-04-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-04-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-04-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-04-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-04-2023,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-04-2023,0,0
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-04-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-04-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-04-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-04-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-04-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-04-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-04-2023,0,0
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-04-2023,0,0
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-04-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-04-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-04-2023,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-04-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-04-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-04-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-04-2023,0,0
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-04-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-04-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-04-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-04-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-04-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-04-2023,0,0
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-04-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-04-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-04-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-04-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-04-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-04-2023,34769,0.488974208
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-04-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-04-2023,2316,0.032571091
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-04-2023,16,0.000225016
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2023,430,0.00604731
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-04-2023,0,0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-04-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2023,455,0.006398897
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-04-2023,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-04-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-04-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-04-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-04-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-04-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-04-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-04-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-04-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-04-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2023,62,0.000871938
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-04-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2023,204,0.002868956
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-04-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-04-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-04-2023,44,0.000618794
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-04-2023,0,0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-04-2023,2639,0.037113605
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-04-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-04-2023,1130,0.015891767
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-04-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-04-2023,333,0.004683149
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-04-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-04-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-04-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-04-2023,320,0.004500323
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-04-2023,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-04-2023,4,0.129032258
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-04-2023,15,0.483870968
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-04-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-04-2023,15,0.483870968
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-04-2023,0,0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-04-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-04-2023,0,0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-04-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-04-2023,0,0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-04-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-04-2023,159,0.115050651
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-04-2023,159,0.115050651
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-04-2023,15,0.010853835
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-04-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-04-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-04-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-04-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-04-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-04-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-04-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-04-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-04-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-04-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-04-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-04-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-04-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-05-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-05-2023,146,0.092229943
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-05-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-05-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-05-2023,0,0
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-05-2023,42,0.026531901
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-05-2023,42,0.026531901
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-05-2023,42,0.026531901
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-05-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-05-2023,20,0.012634239
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-05-2023,15,0.009475679
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-05-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-05-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-05-2023,443,0.279848389
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-05-2023,23,0.014529375
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-05-2023,443,0.279848389
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-05-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-05-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-05-2023,0,0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-05-2023,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-05-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-05-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-05-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-05-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-05-2023,110,0.57591623
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-05-2023,54,0.282722513
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-05-2023,34,0.178010471
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-05-2023,110,0.57591623
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-05-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-05-2023,10,0.052356021
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-05-2023,100,0.523560209
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-05-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-05-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-05-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-05-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-05-2023,56,0.525773196
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-05-2023,7,0.020618557
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-05-2023,56,0.525773196
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-05-2023,60,0.314136126
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-05-2023,49,0.256544503
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-05-2023,9,0.047120419
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-05-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-05-2023,109,0.570680628
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-05-2023,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-05-2023,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-05-2023,109,0.570680628
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-05-2023,109,0.570680628
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-05-2023,109,0.570680628
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-05-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-05-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-05-2023,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-05-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-05-2023,109,0.524038462
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-05-2023,109,0.524038462
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-05-2023,109,0.524038462
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-05-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-05-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-05-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-05-2023,19,0.049222798
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-05-2023,4,0.010362694
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-05-2023,10,0.025906736
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-05-2023,4,0.010362694
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-05-2023,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-05-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-05-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-05-2023,7,0.018134715
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-05-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-05-2023,9,0.023316062
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-05-2023,12,0.031088083
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-05-2023,6,0.015544041
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-05-2023,2,0.005181347
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-05-2023,22,0.056994819
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-05-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-05-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-05-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-05-2023,0,0
M8,Family Planning,8.17.1,Complications following male sterilization,01-05-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-05-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-05-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-05-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-05-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-05-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-05-2023,9,0.023316062
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-05-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-05-2023,109,0.576719577
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-05-2023,109,0.576719577
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-05-2023,25,0.132275132
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-05-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-05-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-05-2023,109,0.576719577
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-05-2023,25,0.132275132
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-05-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-05-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-05-2023,109,0.576719577
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-05-2023,25,0.132275132
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-05-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-05-2023,25,0.132275132
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-05-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-05-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-05-2023,25,0.132275132
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-05-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-05-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-05-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-05-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-05-2023,8,0.042328042
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-05-2023,8,0.042328042
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-05-2023,9,0.047619048
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-05-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-05-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-05-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-05-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-05-2023,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-05-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-05-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-05-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-05-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-05-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-05-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-05-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-05-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-05-2023,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-05-2023,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-05-2023,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-05-2023,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-05-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-05-2023,2,0.016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-05-2023,6,0.050847458
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-05-2023,24,0.090225564
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-05-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-05-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-05-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-05-2023,33,0.12406015
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-05-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-05-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-05-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-05-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-05-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-05-2023,0,0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-05-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-05-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-05-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-05-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-05-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-05-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-05-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-05-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-05-2023,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-05-2023,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-05-2023,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-05-2023,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-05-2023,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-05-2023,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-05-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-05-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-05-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-05-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-05-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-05-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-05-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-05-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-05-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-05-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-05-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-05-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-05-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-05-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-05-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-05-2023,712,0.018787767
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-05-2023,670,0.0176795
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-05-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-05-2023,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-05-2023,178,0.004696942
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-05-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-05-2023,1389,0.036651978
M14,Patient Services,14.1.8,Outpatient - Dental,01-05-2023,919,0.024249941
M14,Patient Services,14.1.9,Outpatient - ENT ,01-05-2023,1035,0.027310869
M14,Patient Services,14.1.10,Outpatients- Asthma,01-05-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-05-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-05-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-05-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-05-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-05-2023,12,0.000316648
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-05-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-05-2023,1055,0.027838615
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-05-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-05-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-05-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-05-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-05-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-05-2023,634,0.016729556
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-05-2023,0,0
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-05-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-05-2023,18315,0.483283637
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-05-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-05-2023,130,0.003430351
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-05-2023,530,0.013985276
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-05-2023,100,0.002638731
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-05-2023,651,0.017178141
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-05-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-05-2023,125,0.003298414
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-05-2023,525,0.013853339
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-05-2023,88,0.002322084
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-05-2023,640,0.01688788
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-05-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-05-2023,3,7.92E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-05-2023,3,7.92E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-05-2023,0,0
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-05-2023,3,7.92E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-05-2023,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-05-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-05-2023,10,0.000263873
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-05-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-05-2023,1,2.64E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-05-2023,11,0.00029026
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-05-2023,4,0.000105549
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-05-2023,1,2.64E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-05-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-05-2023,41,0.00108188
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-05-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-05-2023,361,0.00952582
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-05-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-05-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-05-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-05-2023,5,0.000131937
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-05-2023,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-05-2023,41,0.00108188
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-05-2023,3,7.92E-05
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-05-2023,16,0.000422197
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-05-2023,11,0.00029026
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-05-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-05-2023,111,0.002928992
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-05-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-05-2023,1512,0.039897617
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-05-2023,470,0.012402037
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-05-2023,104,0.002744281
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-05-2023,7,0.000184711
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-05-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-05-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-05-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-05-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-05-2023,26,0.00068607
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-05-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-05-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-05-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-05-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-05-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-05-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-05-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-05-2023,6,0.000158324
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-05-2023,537,0.014169987
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-05-2023,26,0.00068607
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-05-2023,309,0.00815368
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-05-2023,4,0.000105549
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-05-2023,20,0.000527746
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-05-2023,2,5.28E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-05-2023,0,0
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-05-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-05-2023,7351,0.193973138
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-05-2023,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-05-2023,0,0
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-05-2023,0,0
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-05-2023,0,0
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-05-2023,0,0
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-05-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-05-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-05-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-05-2023,109,0.002876217
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-05-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-05-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-05-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-05-2023,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-05-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-05-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-05-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-05-2023,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-05-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-05-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-05-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-05-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-05-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-05-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-05-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-05-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-05-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-05-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-05-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-05-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-05-2023,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-05-2023,0,0
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-05-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-05-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-05-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-05-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-05-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-05-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-05-2023,0,0
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-05-2023,0,0
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-05-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-05-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-05-2023,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-05-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-05-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-05-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-05-2023,0,0
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-05-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-05-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-05-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-05-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-05-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-05-2023,0,0
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-05-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-05-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-05-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-05-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-05-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-05-2023,41196,0.579360392
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-05-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-05-2023,3256,0.045790791
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-05-2023,21,0.000295334
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2023,385,0.005414452
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-05-2023,0,0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2023,2,2.81E-05
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-05-2023,2,2.81E-05
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2023,506,0.007116136
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-05-2023,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2023,2,2.81E-05
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-05-2023,2,2.81E-05
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-05-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-05-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-05-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-05-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-05-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-05-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-05-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-05-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-05-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2023,70,0.000984446
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-05-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2023,158,0.002222035
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-05-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-05-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-05-2023,49,0.000689112
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-05-2023,0,0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-05-2023,2728,0.038365258
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-05-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-05-2023,1291,0.018155992
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-05-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-05-2023,390,0.005484769
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-05-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-05-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-05-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-05-2023,400,0.005625404
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-05-2023,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-05-2023,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-05-2023,22,0.709677419
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-05-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-05-2023,22,0.709677419
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-05-2023,0,0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-05-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-05-2023,0,0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-05-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-05-2023,0,0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-05-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-05-2023,140,0.10130246
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-05-2023,140,0.10130246
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-05-2023,14,0.010130246
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-05-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-05-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-05-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-05-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-05-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-05-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-05-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-05-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-05-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-05-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-05-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-05-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-05-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-06-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-06-2023,235,0.148452306
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-06-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-06-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-06-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-06-2023,42,0.026531901
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-06-2023,28,0.017687934
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-06-2023,28,0.017687934
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-06-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-06-2023,82,0.051800379
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-06-2023,62,0.03916614
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-06-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-06-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-06-2023,262,0.165508528
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-06-2023,36,0.02274163
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-06-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-06-2023,262,0.165508528
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-06-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-06-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-06-2023,0,0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-06-2023,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-06-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-06-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-06-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-06-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-06-2023,117,0.612565445
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-06-2023,61,0.319371728
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-06-2023,32,0.167539267
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-06-2023,117,0.612565445
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-06-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-06-2023,14,0.073298429
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-06-2023,103,0.539267016
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-06-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-06-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-06-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-06-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-06-2023,56,0.525773196
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-06-2023,6,0.010309278
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-06-2023,56,0.525773196
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-06-2023,58,0.303664921
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-06-2023,54,0.282722513
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-06-2023,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-06-2023,5,0.02617801
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-06-2023,112,0.586387435
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-06-2023,8,0.041884817
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-06-2023,112,0.586387435
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-06-2023,112,0.586387435
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-06-2023,112,0.586387435
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-06-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-06-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-06-2023,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-06-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-06-2023,110,0.528846154
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-06-2023,112,0.538461538
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-06-2023,112,0.538461538
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-06-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-06-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-06-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-06-2023,5,0.012953368
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-06-2023,2,0.005181347
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-06-2023,11,0.028497409
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-06-2023,1,0.002590674
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-06-2023,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-06-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-06-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-06-2023,6,0.015544041
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-06-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-06-2023,10,0.025906736
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-06-2023,12,0.031088083
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-06-2023,8,0.020725389
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-06-2023,2,0.005181347
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-06-2023,32,0.082901554
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-06-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-06-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-06-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-06-2023,0,0
M8,Family Planning,8.17.1,Complications following male sterilization,01-06-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-06-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-06-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-06-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-06-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-06-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-06-2023,20,0.051813472
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-06-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-06-2023,112,0.592592593
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-06-2023,112,0.592592593
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-06-2023,40,0.211640212
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-06-2023,44,0.232804233
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-06-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-06-2023,112,0.592592593
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-06-2023,40,0.211640212
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-06-2023,44,0.232804233
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-06-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-06-2023,112,0.592592593
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-06-2023,40,0.211640212
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-06-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-06-2023,40,0.211640212
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-06-2023,44,0.232804233
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-06-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-06-2023,40,0.211640212
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-06-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-06-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-06-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-06-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-06-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-06-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-06-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-06-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-06-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-06-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-06-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-06-2023,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-06-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-06-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-06-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-06-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-06-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-06-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-06-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-06-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-06-2023,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-06-2023,2,0.016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-06-2023,5,0.042372881
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-06-2023,5,0.042372881
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-06-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-06-2023,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-06-2023,6,0.050847458
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-06-2023,28,0.105263158
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-06-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-06-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-06-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-06-2023,47,0.176691729
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-06-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-06-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-06-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-06-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-06-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-06-2023,0,0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-06-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-06-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-06-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-06-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-06-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-06-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-06-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-06-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-06-2023,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-06-2023,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-06-2023,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-06-2023,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-06-2023,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-06-2023,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-06-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-06-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-06-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-06-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-06-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-06-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-06-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-06-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-06-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-06-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-06-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-06-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-06-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-06-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-06-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-06-2023,770,0.020318231
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-06-2023,680,0.017943373
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-06-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-06-2023,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-06-2023,223,0.005884371
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-06-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-06-2023,1365,0.036018682
M14,Patient Services,14.1.8,Outpatient - Dental,01-06-2023,287,0.007573159
M14,Patient Services,14.1.9,Outpatient - ENT ,01-06-2023,950,0.025067947
M14,Patient Services,14.1.10,Outpatients- Asthma,01-06-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-06-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-06-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-06-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-06-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-06-2023,15,0.00039581
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-06-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-06-2023,1040,0.027442805
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-06-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-06-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-06-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-06-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-06-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-06-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-06-2023,734,0.019368288
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-06-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-06-2023,19063,0.503021347
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-06-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-06-2023,79,0.002084598
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-06-2023,645,0.017019817
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-06-2023,95,0.002506795
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-06-2023,636,0.016782331
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-06-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-06-2023,122,0.003219252
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-06-2023,588,0.01551574
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-06-2023,99,0.002612344
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-06-2023,654,0.017257303
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-06-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-06-2023,3,7.92E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-06-2023,2,5.28E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-06-2023,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-06-2023,3,7.92E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-06-2023,4,0.000105549
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-06-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-06-2023,8,0.000211099
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-06-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-06-2023,3,7.92E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-06-2023,10,0.000263873
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-06-2023,2,5.28E-05
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-06-2023,1,2.64E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-06-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-06-2023,45,0.001187429
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-06-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-06-2023,346,0.00913001
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-06-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-06-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-06-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-06-2023,9,0.000237486
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-06-2023,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-06-2023,38,0.001002718
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-06-2023,5,0.000131937
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-06-2023,12,0.000316648
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-06-2023,14,0.000369422
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-06-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-06-2023,130,0.003430351
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-06-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-06-2023,1276,0.033670211
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-06-2023,355,0.009367496
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-06-2023,71,0.001873499
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-06-2023,3,7.92E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-06-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-06-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-06-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-06-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-06-2023,30,0.000791619
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-06-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-06-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-06-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-06-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-06-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-06-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-06-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-06-2023,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-06-2023,538,0.014196374
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-06-2023,24,0.000633296
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-06-2023,320,0.00844394
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-06-2023,2,5.28E-05
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-06-2023,18,0.000474972
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-06-2023,2,5.28E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-06-2023,0,0
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-06-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-06-2023,7950,0.209779138
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-06-2023,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-06-2023,0,0
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-06-2023,0,0
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-06-2023,0,0
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-06-2023,0,0
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-06-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-06-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-06-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-06-2023,112,0.002955379
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-06-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-06-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-06-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-06-2023,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-06-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-06-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-06-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-06-2023,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-06-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-06-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-06-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-06-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-06-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-06-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-06-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-06-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-06-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-06-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-06-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-06-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-06-2023,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-06-2023,0,0
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-06-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-06-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-06-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-06-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-06-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-06-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-06-2023,0,0
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-06-2023,0,0
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-06-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-06-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-06-2023,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-06-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-06-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-06-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-06-2023,0,0
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-06-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-06-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-06-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-06-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-06-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-06-2023,0,0
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-06-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-06-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-06-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-06-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-06-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-06-2023,40798,0.573763114
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-06-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-06-2023,3146,0.044243805
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-06-2023,21,0.000295334
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2023,441,0.006202008
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-06-2023,0,0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2023,4,5.63E-05
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-06-2023,4,5.63E-05
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2023,534,0.007509915
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-06-2023,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2023,3,4.22E-05
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-06-2023,3,4.22E-05
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-06-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-06-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-06-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-06-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-06-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-06-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-06-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-06-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-06-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2023,66,0.000928192
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-06-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2023,209,0.002939274
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-06-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-06-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-06-2023,82,0.001153208
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-06-2023,0,0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-06-2023,3017,0.042429612
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-06-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-06-2023,1377,0.019365454
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-06-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-06-2023,390,0.005484769
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-06-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-06-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-06-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-06-2023,415,0.005836357
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-06-2023,4,0.129032258
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-06-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-06-2023,21,0.677419355
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-06-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-06-2023,21,0.677419355
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-06-2023,0,0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-06-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-06-2023,0,0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-06-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-06-2023,0,0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-06-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-06-2023,173,0.125180897
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-06-2023,173,0.125180897
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-06-2023,12,0.008683068
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-06-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-06-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-06-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-06-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-06-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-06-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-06-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-06-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-06-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-06-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-06-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-06-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-06-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-07-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-07-2023,978,0.617814277
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-07-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-07-2023,14,0.008843967
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-07-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-07-2023,33,0.020846494
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-07-2023,24,0.015161087
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-07-2023,24,0.015161087
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-07-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-07-2023,56,0.035375869
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-07-2023,342,0.216045483
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-07-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-07-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-07-2023,343,0.216677195
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-07-2023,23,0.014529375
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-07-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-07-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-07-2023,356,0.22488945
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-07-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-07-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-07-2023,78,0.049273531
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-07-2023,62,0.03916614
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-07-2023,15,0.009475679
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-07-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-07-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-07-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-07-2023,112,0.070751737
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-07-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-07-2023,32,0.020214782
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-07-2023,21,0.013265951
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-07-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-07-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-07-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-07-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-07-2023,107,0.560209424
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-07-2023,50,0.261780105
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-07-2023,25,0.130890052
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-07-2023,107,0.560209424
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-07-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-07-2023,10,0.052356021
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-07-2023,97,0.507853403
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-07-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-07-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-07-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-07-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-07-2023,57,0.536082474
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-07-2023,5,0
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-07-2023,57,0.536082474
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-07-2023,54,0.282722513
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-07-2023,52,0.272251309
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-07-2023,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-07-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-07-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-07-2023,26,0.136125654
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-07-2023,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-07-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-07-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-07-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-07-2023,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-07-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-07-2023,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-07-2023,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-07-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-07-2023,6,0.12
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-07-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-07-2023,106,0.509615385
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-07-2023,106,0.509615385
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-07-2023,106,0.509615385
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-07-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-07-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-07-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-07-2023,5,0.012953368
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-07-2023,2,0.005181347
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-07-2023,4,0.010362694
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-07-2023,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-07-2023,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-07-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-07-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-07-2023,6,0.015544041
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-07-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-07-2023,12,0.031088083
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-07-2023,10,0.025906736
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-07-2023,12,0.031088083
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-07-2023,8,0.020725389
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-07-2023,30,0.077720207
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-07-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-07-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-07-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-07-2023,252,0.652849741
M8,Family Planning,8.17.1,Complications following male sterilization,01-07-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-07-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-07-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-07-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-07-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-07-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-07-2023,12,0.031088083
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-07-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-07-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-07-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-07-2023,43,0.227513228
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-07-2023,46,0.243386243
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-07-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-07-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-07-2023,43,0.227513228
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-07-2023,46,0.243386243
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-07-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-07-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-07-2023,43,0.227513228
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-07-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-07-2023,43,0.227513228
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-07-2023,46,0.243386243
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-07-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-07-2023,43,0.227513228
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-07-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-07-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-07-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-07-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-07-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-07-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-07-2023,10,0.052910053
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-07-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-07-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-07-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-07-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-07-2023,4,0.021164021
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-07-2023,16,0.084656085
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-07-2023,6,0.031746032
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-07-2023,10,0.052910053
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-07-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-07-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-07-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-07-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-07-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-07-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-07-2023,11,0.093220339
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-07-2023,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-07-2023,60,0.508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-07-2023,60,0.508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-07-2023,60,0.508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-07-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-07-2023,8,0.06779661
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-07-2023,40,0.15037594
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-07-2023,1,0.003759398
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-07-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-07-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-07-2023,55,0.206766917
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-07-2023,1,0.003759398
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-07-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-07-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-07-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-07-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-07-2023,2,0.007518797
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-07-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-07-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-07-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-07-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-07-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-07-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-07-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-07-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-07-2023,19,0.150793651
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-07-2023,8,0.063492063
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-07-2023,12,0.095238095
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-07-2023,6,0.047619048
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-07-2023,19,0.150793651
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-07-2023,8,0.063492063
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-07-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-07-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-07-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-07-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-07-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-07-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-07-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-07-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-07-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-07-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-07-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-07-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-07-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-07-2023,1,0.1
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-07-2023,8,0.8
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-07-2023,8,0.8
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-07-2023,8,0.8
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-07-2023,1,0.1
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-07-2023,1,0.1
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-07-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-07-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-07-2023,820,0.021637597
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-07-2023,730,0.019262738
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-07-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-07-2023,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-07-2023,0,0
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-07-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-07-2023,1524,0.040214265
M14,Patient Services,14.1.8,Outpatient - Dental,01-07-2023,1000,0.026387313
M14,Patient Services,14.1.9,Outpatient - ENT ,01-07-2023,1003,0.026466475
M14,Patient Services,14.1.10,Outpatients- Asthma,01-07-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-07-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-07-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-07-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-07-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-07-2023,17,0.000448584
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-07-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-07-2023,1375,0.036282555
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-07-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-07-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-07-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-07-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-07-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-07-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-07-2023,761,0.020080745
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-07-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-07-2023,20585,0.543182838
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-07-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-07-2023,138,0.003641449
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-07-2023,587,0.015489353
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-07-2023,99,0.002612344
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-07-2023,695,0.018339183
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-07-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-07-2023,140,0.003694224
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-07-2023,593,0.015647677
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-07-2023,101,0.002665119
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-07-2023,663,0.017494789
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-07-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-07-2023,2,5.28E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-07-2023,0,0
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-07-2023,0,0
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-07-2023,0,0
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-07-2023,9,0.000237486
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-07-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-07-2023,0,0
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-07-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-07-2023,0,0
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-07-2023,0,0
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-07-2023,7,0.000184711
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-07-2023,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-07-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-07-2023,0,0
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-07-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-07-2023,0,0
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-07-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-07-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-07-2023,1,2.64E-05
M14,Patient Services,14.4.2,Inpatient - Dengue,01-07-2023,20,0.000527746
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-07-2023,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-07-2023,42,0.001108267
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-07-2023,2,5.28E-05
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-07-2023,6,0.000158324
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-07-2023,12,0.000316648
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-07-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-07-2023,150,0.003958097
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-07-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-07-2023,1902,0.050188669
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-07-2023,455,0.012006227
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-07-2023,55,0.001451302
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-07-2023,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-07-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-07-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-07-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-07-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-07-2023,2,5.28E-05
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-07-2023,1,2.64E-05
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-07-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-07-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-07-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-07-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-07-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-07-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-07-2023,3,7.92E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-07-2023,587,0.015489353
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-07-2023,21,0.000554134
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-07-2023,320,0.00844394
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-07-2023,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-07-2023,62,0.001636013
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-07-2023,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-07-2023,2,5.28E-05
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-07-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-07-2023,8268,0.218170304
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-07-2023,41,0.00108188
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-07-2023,18,0.000474972
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-07-2023,21,0.000554134
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-07-2023,1,2.64E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-07-2023,1,2.64E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-07-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-07-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-07-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-07-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-07-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-07-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-07-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-07-2023,5,0.000131937
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-07-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-07-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-07-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-07-2023,5,0.000131937
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-07-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-07-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-07-2023,1,2.64E-05
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-07-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-07-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-07-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-07-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-07-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-07-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-07-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-07-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-07-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-07-2023,197,0.005198301
M14,Patient Services,14.21,Total number of blood units issued in month,01-07-2023,267,0.007045413
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-07-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-07-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-07-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-07-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-07-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-07-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-07-2023,940,0.024804074
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-07-2023,815,0.02150566
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-07-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-07-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-07-2023,11,0.00029026
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-07-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-07-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-07-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-07-2023,3,7.92E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-07-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-07-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-07-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-07-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-07-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-07-2023,356,0.009393883
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-07-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-07-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-07-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-07-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-07-2023,3,7.92E-05
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-07-2023,42062,0.591539392
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-07-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-07-2023,3645,0.051261497
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-07-2023,645,0.009070964
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2023,452,0.006356707
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-07-2023,3,4.22E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-07-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2023,551,0.007748994
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-07-2023,3,4.22E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-07-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-07-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-07-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-07-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-07-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-07-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-07-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-07-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-07-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2023,89,0.001251652
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-07-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2023,185,0.00260175
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-07-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-07-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-07-2023,53,0.000745366
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-07-2023,2,2.81E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-07-2023,3024,0.042528057
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-07-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-07-2023,1418,0.019942058
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-07-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-07-2023,362,0.005090991
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-07-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-07-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-07-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-07-2023,450,0.00632858
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-07-2023,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-07-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-07-2023,28,0.903225806
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-07-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-07-2023,28,0.903225806
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-07-2023,13,0.009406657
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-07-2023,13,0.009406657
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-07-2023,47,0.034008683
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-07-2023,45,0.032561505
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-07-2023,73,0.052821997
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-07-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-07-2023,0,0
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-07-2023,0,0
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-07-2023,0,0
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-07-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-07-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-07-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-07-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-07-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-07-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-07-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-07-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-07-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-07-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-07-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-07-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-07-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-08-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-08-2023,356,0.22488945
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-08-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-08-2023,15,0.009475679
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-08-2023,16,0.010107391
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-08-2023,29,0.018319646
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-08-2023,28,0.017687934
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-08-2023,28,0.017687934
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-08-2023,44,0.027795325
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-08-2023,29,0.018319646
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-08-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-08-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-08-2023,138,0.087176248
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-08-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-08-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-08-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-08-2023,138,0.087176248
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-08-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-08-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-08-2023,138,0.087176248
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-08-2023,106,0.066961466
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-08-2023,13,0.008212255
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-08-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-08-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-08-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-08-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-08-2023,56,0.035375869
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-08-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-08-2023,34,0.021478206
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-08-2023,28,0.017687934
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-08-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-08-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-08-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-08-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-08-2023,125,0.654450262
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-08-2023,67,0.35078534
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-08-2023,23,0.120418848
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-08-2023,125,0.654450262
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-08-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-08-2023,0,0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-08-2023,125,0.654450262
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-08-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-08-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-08-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-08-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-08-2023,58,0.546391753
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-08-2023,9,0.041237113
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-08-2023,58,0.546391753
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-08-2023,67,0.35078534
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-08-2023,58,0.303664921
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-08-2023,9,0.047120419
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-08-2023,125,0.654450262
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-08-2023,25,0.130890052
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-08-2023,11,0.057591623
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-08-2023,125,0.654450262
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-08-2023,125,0.654450262
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-08-2023,125,0.654450262
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-08-2023,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-08-2023,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-08-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-08-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-08-2023,12,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-08-2023,125,0.600961538
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-08-2023,125,0.600961538
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-08-2023,125,0.600961538
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-08-2023,125,0.600961538
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-08-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-08-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-08-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-08-2023,2,0.005181347
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-08-2023,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-08-2023,12,0.031088083
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-08-2023,3,0.007772021
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-08-2023,12,0.031088083
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-08-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-08-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-08-2023,10,0.025906736
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-08-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-08-2023,8,0.020725389
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-08-2023,6,0.015544041
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-08-2023,2,0.005181347
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-08-2023,0,0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-08-2023,40,0.103626943
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-08-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-08-2023,2,0.005181347
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-08-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-08-2023,386,1
M8,Family Planning,8.17.1,Complications following male sterilization,01-08-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-08-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-08-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-08-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-08-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-08-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-08-2023,13,0.033678756
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-08-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-08-2023,125,0.661375661
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-08-2023,125,0.661375661
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-08-2023,37,0.195767196
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-08-2023,23,0.121693122
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-08-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-08-2023,125,0.661375661
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-08-2023,37,0.195767196
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-08-2023,23,0.121693122
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-08-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-08-2023,125,0.661375661
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-08-2023,37,0.195767196
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-08-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-08-2023,37,0.195767196
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-08-2023,23,0.121693122
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-08-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-08-2023,37,0.195767196
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-08-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-08-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-08-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-08-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-08-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-08-2023,9,0.047619048
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-08-2023,10,0.052910053
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-08-2023,1,0.005291005
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-08-2023,15,0.079365079
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-08-2023,15,0.079365079
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-08-2023,15,0.079365079
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-08-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-08-2023,6,0.031746032
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-08-2023,3,0.015873016
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-08-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-08-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-08-2023,4,0.021164021
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-08-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-08-2023,1,0.005291005
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-08-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-08-2023,19,0.100529101
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-08-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-08-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-08-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-08-2023,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-08-2023,48,0.406779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-08-2023,48,0.406779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-08-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-08-2023,72,0.610169492
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-08-2023,21,0.177966102
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-08-2023,8,0.06779661
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-08-2023,98,0.368421053
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-08-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-08-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-08-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-08-2023,81,0.304511278
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-08-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-08-2023,1,0.003759398
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-08-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-08-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-08-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-08-2023,8,0.030075188
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-08-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-08-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-08-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-08-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-08-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-08-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-08-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-08-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-08-2023,20,0.158730159
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-08-2023,8,0.063492063
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-08-2023,14,0.111111111
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-08-2023,5,0.03968254
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-08-2023,20,0.158730159
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-08-2023,8,0.063492063
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-08-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-08-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-08-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-08-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-08-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-08-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-08-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-08-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-08-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-08-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-08-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-08-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-08-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-08-2023,6,0.6
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-08-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-08-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-08-2023,929,0.024513814
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-08-2023,775,0.020450168
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-08-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-08-2023,2,5.28E-05
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-08-2023,276,0.007282898
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-08-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-08-2023,1447,0.038182442
M14,Patient Services,14.1.8,Outpatient - Dental,01-08-2023,993,0.026202602
M14,Patient Services,14.1.9,Outpatient - ENT ,01-08-2023,1074,0.028339974
M14,Patient Services,14.1.10,Outpatients- Asthma,01-08-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-08-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-08-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-08-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-08-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-08-2023,18,0.000474972
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-08-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-08-2023,1150,0.03034541
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-08-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-08-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-08-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-08-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-08-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-08-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-08-2023,680,0.017943373
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-08-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-08-2023,21728,0.573343536
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-08-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-08-2023,184,0.004855266
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-08-2023,704,0.018576668
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-08-2023,160,0.00422197
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-08-2023,760,0.020054358
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-08-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-08-2023,163,0.004301132
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-08-2023,685,0.018075309
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-08-2023,129,0.003403963
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-08-2023,768,0.020265456
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-08-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-08-2023,1,2.64E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-08-2023,1,2.64E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-08-2023,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-08-2023,3,7.92E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-08-2023,3,7.92E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-08-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-08-2023,10,0.000263873
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-08-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-08-2023,5,0.000131937
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-08-2023,13,0.000343035
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-08-2023,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-08-2023,5,0.000131937
M14,Patient Services,14.3.6,Day Care Admissions,01-08-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-08-2023,35,0.000923556
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-08-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-08-2023,0,0
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-08-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-08-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-08-2023,1,2.64E-05
M14,Patient Services,14.4.2,Inpatient - Dengue,01-08-2023,34,0.000897169
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-08-2023,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-08-2023,68,0.001794337
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-08-2023,2,5.28E-05
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-08-2023,6,0.000158324
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-08-2023,11,0.00029026
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-08-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-08-2023,119,0.00314009
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-08-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-08-2023,1209,0.031902261
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-08-2023,295,0.007784257
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-08-2023,45,0.001187429
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-08-2023,3,7.92E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-08-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-08-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-08-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-08-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-08-2023,11,0.00029026
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-08-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-08-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-08-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-08-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-08-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-08-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-08-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-08-2023,1,2.64E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-08-2023,543,0.014328311
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-08-2023,31,0.000818007
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-08-2023,285,0.007520384
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-08-2023,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-08-2023,55,0.001451302
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-08-2023,5,0.000131937
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-08-2023,2,5.28E-05
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-08-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-08-2023,9037,0.238462147
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-08-2023,59,0.001556851
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-08-2023,37,0.000976331
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-08-2023,10,0.000263873
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-08-2023,6,0.000158324
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-08-2023,6,0.000158324
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-08-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-08-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-08-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-08-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-08-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-08-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-08-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-08-2023,4,0.000105549
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-08-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-08-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-08-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-08-2023,3,7.92E-05
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-08-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-08-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-08-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-08-2023,1,2.64E-05
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-08-2023,4,0.000105549
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-08-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-08-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-08-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-08-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-08-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-08-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-08-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-08-2023,187,0.004934428
M14,Patient Services,14.21,Total number of blood units issued in month,01-08-2023,245,0.006464892
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-08-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-08-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-08-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-08-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-08-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-08-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-08-2023,960,0.02533182
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-08-2023,797,0.021030688
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-08-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-08-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-08-2023,9,0.000237486
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-08-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-08-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-08-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-08-2023,2,5.28E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-08-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-08-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-08-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-08-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-08-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-08-2023,738,0.019473837
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-08-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-08-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-08-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-08-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-08-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-08-2023,44726,0.629004585
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-08-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-08-2023,3648,0.051303687
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-08-2023,29,0.000407842
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2023,399,0.005611341
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-08-2023,2,2.81E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-08-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2023,479,0.006736422
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-08-2023,1,1.41E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-08-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-08-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-08-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-08-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-08-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-08-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-08-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-08-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-08-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2023,56,0.000787557
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-08-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2023,226,0.003178353
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-08-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-08-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-08-2023,121,0.001701685
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-08-2023,11,0.000154699
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-08-2023,2858,0.040193514
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-08-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-08-2023,1433,0.020153011
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-08-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-08-2023,202,0.002840829
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-08-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-08-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-08-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-08-2023,501,0.007045819
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-08-2023,10,0.322580645
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-08-2023,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-08-2023,28,0.903225806
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-08-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-08-2023,28,0.903225806
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-08-2023,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-08-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-08-2023,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-08-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-08-2023,83,0.060057887
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-08-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-08-2023,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-08-2023,3,0.002170767
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-08-2023,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-08-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-08-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-08-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-08-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-08-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-08-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-08-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-08-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-08-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-08-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-08-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-08-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-08-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-09-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-09-2023,1266,0.799747315
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-09-2023,11,0.006948831
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-09-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-09-2023,5,0.00315856
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-09-2023,32,0.020214782
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-09-2023,52,0.032849021
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-09-2023,52,0.032849021
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-09-2023,162,0.102337334
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-09-2023,112,0.070751737
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-09-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-09-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-09-2023,496,0.313329122
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-09-2023,42,0.026531901
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-09-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-09-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-09-2023,480,0.303221731
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-09-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-09-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-09-2023,496,0.313329122
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-09-2023,122,0.077068857
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-09-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-09-2023,32,0.020214782
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-09-2023,7,0.004421984
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-09-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-09-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-09-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-09-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-09-2023,106,0.554973822
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-09-2023,54,0.282722513
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-09-2023,15,0.078534031
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-09-2023,106,0.554973822
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-09-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-09-2023,4,0.020942408
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-09-2023,102,0.534031414
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-09-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-09-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-09-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-09-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-09-2023,52,0.484536082
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-09-2023,8,0.030927835
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-09-2023,52,0.484536082
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-09-2023,53,0.277486911
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-09-2023,53,0.277486911
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-09-2023,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-09-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-09-2023,7,0.036649215
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-09-2023,5,0.02617801
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-09-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-09-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-09-2023,106,0.554973822
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-09-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-09-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-09-2023,2,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-09-2023,94,0.451923077
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-09-2023,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-09-2023,0,0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-09-2023,0,0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-09-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-09-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-09-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-09-2023,7,0.018134715
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-09-2023,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-09-2023,8,0.020725389
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-09-2023,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-09-2023,8,0.020725389
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-09-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-09-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-09-2023,3,0.007772021
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-09-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-09-2023,4,0.010362694
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-09-2023,7,0.018134715
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-09-2023,8,0.020725389
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-09-2023,3,0.007772021
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-09-2023,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-09-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-09-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-09-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-09-2023,309,0.800518135
M8,Family Planning,8.17.1,Complications following male sterilization,01-09-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-09-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-09-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-09-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-09-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-09-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-09-2023,18,0.046632124
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-09-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-09-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-09-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-09-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-09-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-09-2023,24,0.126984127
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-09-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-09-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-09-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-09-2023,24,0.126984127
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-09-2023,106,0.560846561
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-09-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-09-2023,24,0.126984127
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-09-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-09-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-09-2023,24,0.126984127
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-09-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-09-2023,24,0.126984127
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-09-2023,7,0.037037037
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-09-2023,11,0.058201058
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-09-2023,18,0.095238095
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-09-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-09-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-09-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-09-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-09-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-09-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-09-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-09-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-09-2023,17,0.08994709
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-09-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-09-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-09-2023,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-09-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-09-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-09-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-09-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-09-2023,45,0.381355932
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-09-2023,27,0.228813559
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-09-2023,3,0.025423729
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-09-2023,101,0.379699248
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-09-2023,1,0.003759398
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-09-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-09-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-09-2023,87,0.327067669
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-09-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-09-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-09-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-09-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-09-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-09-2023,5,0.018796992
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-09-2023,5,0.018796992
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-09-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-09-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-09-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-09-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-09-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-09-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-09-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-09-2023,36,0.285714286
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-09-2023,24,0.19047619
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-09-2023,36,0.285714286
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-09-2023,24,0.19047619
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-09-2023,6,0.047619048
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-09-2023,4,0.031746032
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-09-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-09-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-09-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-09-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-09-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-09-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-09-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-09-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-09-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-09-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-09-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-09-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-09-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-09-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-09-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-09-2023,875,0.023088899
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-09-2023,790,0.020845977
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-09-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-09-2023,229,0.006042695
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-09-2023,252,0.006649603
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-09-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-09-2023,1349,0.035596485
M14,Patient Services,14.1.8,Outpatient - Dental,01-09-2023,887,0.023405547
M14,Patient Services,14.1.9,Outpatient - ENT ,01-09-2023,1025,0.027046996
M14,Patient Services,14.1.10,Outpatients- Asthma,01-09-2023,10,0.000263873
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-09-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-09-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-09-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-09-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-09-2023,28,0.000738845
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-09-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-09-2023,1110,0.029289917
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-09-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-09-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-09-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-09-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-09-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-09-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-09-2023,608,0.016043486
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-09-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-09-2023,20380,0.537773439
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-09-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-09-2023,104,0.002744281
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-09-2023,988,0.026070665
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-09-2023,76,0.002005436
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-09-2023,793,0.020925139
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-09-2023,0,0
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-09-2023,114,0.003008154
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-09-2023,1008,0.026598411
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-09-2023,81,0.002137372
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-09-2023,832,0.021954244
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-09-2023,0,0
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-09-2023,1,2.64E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-09-2023,1,2.64E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-09-2023,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-09-2023,3,7.92E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-09-2023,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-09-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-09-2023,5,0.000131937
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-09-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-09-2023,2,5.28E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-09-2023,6,0.000158324
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-09-2023,4,0.000105549
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-09-2023,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-09-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-09-2023,30,0.000791619
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-09-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-09-2023,237,0.006253793
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-09-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-09-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-09-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-09-2023,40,0.001055493
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-09-2023,9,0.000237486
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-09-2023,50,0.001319366
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-09-2023,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-09-2023,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-09-2023,7,0.000184711
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-09-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-09-2023,67,0.00176795
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-09-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-09-2023,1807,0.047681875
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-09-2023,705,0.018603056
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-09-2023,54,0.001424915
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-09-2023,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-09-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-09-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-09-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-09-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-09-2023,10,0.000263873
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-09-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-09-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-09-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-09-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-09-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-09-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-09-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-09-2023,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-09-2023,508,0.013404755
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-09-2023,22,0.000580521
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-09-2023,828,0.021848695
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-09-2023,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-09-2023,86,0.002269309
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-09-2023,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-09-2023,6,0.000158324
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-09-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-09-2023,8871,0.234081853
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-09-2023,43,0.001134654
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-09-2023,24,0.000633296
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-09-2023,9,0.000237486
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-09-2023,8,0.000211099
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-09-2023,2,5.28E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-09-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-09-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-09-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-09-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-09-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-09-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-09-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-09-2023,2,5.28E-05
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-09-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-09-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-09-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-09-2023,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-09-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-09-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-09-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-09-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-09-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-09-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-09-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-09-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-09-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-09-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-09-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-09-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-09-2023,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-09-2023,214,0.005646885
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-09-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-09-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-09-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-09-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-09-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-09-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-09-2023,944,0.024909623
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-09-2023,829,0.021875082
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-09-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-09-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-09-2023,12,0.000316648
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-09-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-09-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-09-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-09-2023,2,5.28E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-09-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-09-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-09-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-09-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-09-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-09-2023,480,0.01266591
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-09-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-09-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-09-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-09-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-09-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-09-2023,45900,0.645515146
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-09-2023,1,1.41E-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-09-2023,4371,0.061471606
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-09-2023,28,0.000393778
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2023,404,0.005681658
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-09-2023,2,2.81E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-09-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2023,656,0.009225663
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-09-2023,3,4.22E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-09-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-09-2023,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-09-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-09-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-09-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-09-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-09-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-09-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-09-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2023,86,0.001209462
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-09-2023,211,0.002967401
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2023,0,0
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-09-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-09-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-09-2023,146,0.002053273
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-09-2023,3,4.22E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-09-2023,2974,0.041824881
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-09-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-09-2023,1408,0.019801423
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-09-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-09-2023,41,0.000576604
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-09-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-09-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-09-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-09-2023,725,0.010196045
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-09-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-09-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-09-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-09-2023,4,0.129032258
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-09-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-09-2023,13,0.419354839
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-09-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-09-2023,13,0.419354839
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-09-2023,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-09-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-09-2023,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-09-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-09-2023,88,0.063675832
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-09-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-09-2023,3,0.002170767
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-09-2023,1,0.000723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-09-2023,1,0.000723589
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-09-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-09-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-09-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-09-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-09-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-09-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-09-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-09-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-09-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-09-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-09-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-09-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-09-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-10-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-10-2023,1583,1
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-10-2023,11,0.006948831
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-10-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-10-2023,6,0.003790272
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-10-2023,32,0.020214782
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-10-2023,48,0.030322173
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-10-2023,48,0.030322173
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-10-2023,347,0.219204043
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-10-2023,48,0.030322173
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-10-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-10-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-10-2023,157,0.099178774
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-10-2023,20,0.012634239
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-10-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-10-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-10-2023,347,0.219204043
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-10-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-10-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-10-2023,347,0.219204043
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-10-2023,21,0.013265951
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-10-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-10-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-10-2023,38,0.024005054
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-10-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-10-2023,18,0.011370815
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-10-2023,20,0.012634239
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-10-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-10-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-10-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-10-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-10-2023,138,0.722513089
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-10-2023,74,0.387434555
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-10-2023,14,0.073298429
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-10-2023,138,0.722513089
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-10-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-10-2023,4,0.020942408
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-10-2023,134,0.701570681
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-10-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-10-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-10-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-10-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-10-2023,64,0.608247423
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-10-2023,11,0.06185567
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-10-2023,64,0.608247423
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-10-2023,67,0.35078534
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-10-2023,69,0.361256545
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-10-2023,20,0.104712042
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-10-2023,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-10-2023,136,0.712041885
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-10-2023,14,0.073298429
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-10-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-10-2023,136,0.712041885
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-10-2023,136,0.712041885
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-10-2023,136,0.712041885
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-10-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-10-2023,2,0.04
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-10-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-10-2023,2,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-10-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-10-2023,187,0.899038462
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-10-2023,187,0.899038462
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-10-2023,187,0.899038462
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-10-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-10-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-10-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-10-2023,6,0.015544041
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-10-2023,1,0.002590674
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-10-2023,4,0.010362694
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-10-2023,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-10-2023,12,0.031088083
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-10-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-10-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-10-2023,8,0.020725389
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-10-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-10-2023,12,0.031088083
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-10-2023,8,0.020725389
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-10-2023,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-10-2023,10,0.025906736
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-10-2023,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-10-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-10-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-10-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-10-2023,72,0.186528497
M8,Family Planning,8.17.1,Complications following male sterilization,01-10-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-10-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-10-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-10-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-10-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-10-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-10-2023,94,0.243523316
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-10-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-10-2023,136,0.71957672
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-10-2023,136,0.71957672
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-10-2023,41,0.216931217
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-10-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-10-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-10-2023,136,0.71957672
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-10-2023,41,0.216931217
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-10-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-10-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-10-2023,136,0.71957672
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-10-2023,41,0.216931217
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-10-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-10-2023,41,0.216931217
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-10-2023,26,0.137566138
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-10-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-10-2023,41,0.216931217
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-10-2023,36,0.19047619
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-10-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-10-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-10-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-10-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-10-2023,12,0.063492063
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-10-2023,10,0.052910053
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-10-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-10-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-10-2023,28,0.148148148
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-10-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-10-2023,1,0.005291005
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-10-2023,1,0.005291005
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-10-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-10-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-10-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-10-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-10-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-10-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-10-2023,10,0.052910053
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-10-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-10-2023,61,0.516949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-10-2023,19,0.161016949
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-10-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-10-2023,51,0.43220339
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-10-2023,51,0.43220339
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-10-2023,51,0.43220339
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-10-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-10-2023,32,0.271186441
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-10-2023,26,0.220338983
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-10-2023,11,0.093220339
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-10-2023,137,0.515037594
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-10-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-10-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-10-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-10-2023,82,0.308270677
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-10-2023,1,0.003759398
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-10-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-10-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-10-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-10-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-10-2023,0,0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-10-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-10-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-10-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-10-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-10-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-10-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-10-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-10-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-10-2023,6,0.047619048
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-10-2023,6,0.047619048
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-10-2023,6,0.047619048
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-10-2023,6,0.047619048
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-10-2023,6,0.047619048
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-10-2023,6,0.047619048
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-10-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-10-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-10-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-10-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-10-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-10-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-10-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-10-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-10-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-10-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-10-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-10-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-10-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-10-2023,10,1
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-10-2023,10,1
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-10-2023,10,1
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-10-2023,10,1
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-10-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-10-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-10-2023,860,0.022693089
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-10-2023,780,0.020582104
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-10-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-10-2023,254,0.006702377
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-10-2023,243,0.006412117
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-10-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-10-2023,1330,0.035095126
M14,Patient Services,14.1.8,Outpatient - Dental,01-10-2023,867,0.0228778
M14,Patient Services,14.1.9,Outpatient - ENT ,01-10-2023,975,0.02572763
M14,Patient Services,14.1.10,Outpatients- Asthma,01-10-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-10-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-10-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-10-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-10-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-10-2023,44,0.001161042
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-10-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-10-2023,0,0
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-10-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-10-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-10-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-10-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-10-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-10-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-10-2023,669,0.017653112
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-10-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-10-2023,20934,0.55239201
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-10-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-10-2023,110,0.002902604
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-10-2023,763,0.02013352
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-10-2023,81,0.002137372
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-10-2023,685,0.018075309
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-10-2023,420,0.011082671
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-10-2023,105,0.002770668
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-10-2023,754,0.019896034
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-10-2023,81,0.002137372
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-10-2023,673,0.017758662
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-10-2023,410,0.010818798
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-10-2023,1,2.64E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-10-2023,0,0
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-10-2023,3,7.92E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-10-2023,9,0.000237486
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-10-2023,2,5.28E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-10-2023,2,5.28E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-10-2023,11,0.00029026
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-10-2023,1,2.64E-05
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-10-2023,2,5.28E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-10-2023,8,0.000211099
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-10-2023,4,0.000105549
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-10-2023,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-10-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-10-2023,27,0.000712457
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-10-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-10-2023,324,0.008549489
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-10-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-10-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-10-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-10-2023,101,0.002665119
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-10-2023,2,5.28E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-10-2023,55,0.001451302
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-10-2023,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-10-2023,6,0.000158324
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-10-2023,14,0.000369422
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-10-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-10-2023,65,0.001715175
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-10-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-10-2023,1180,0.031137029
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-10-2023,883,0.023299997
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-10-2023,36,0.000949943
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-10-2023,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-10-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-10-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-10-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-10-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-10-2023,2,5.28E-05
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-10-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-10-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-10-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-10-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-10-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-10-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-10-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-10-2023,2,5.28E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-10-2023,383,0.010106341
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-10-2023,16,0.000422197
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-10-2023,313,0.008259229
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-10-2023,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-10-2023,82,0.00216376
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-10-2023,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-10-2023,14,0.000369422
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-10-2023,14,0.000369422
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-10-2023,9258,0.244293744
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-10-2023,52,0.00137214
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-10-2023,28,0.000738845
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-10-2023,17,0.000448584
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-10-2023,5,0.000131937
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-10-2023,2,5.28E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-10-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-10-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-10-2023,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-10-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-10-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-10-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-10-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-10-2023,5,0.000131937
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-10-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-10-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-10-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-10-2023,5,0.000131937
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-10-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-10-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-10-2023,1,2.64E-05
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-10-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-10-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-10-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-10-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-10-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-10-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-10-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-10-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-10-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-10-2023,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-10-2023,214,0.005646885
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-10-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-10-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-10-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-10-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-10-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-10-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-10-2023,973,0.025674856
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-10-2023,841,0.02219173
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-10-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-10-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-10-2023,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-10-2023,10,0.000263873
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-10-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-10-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-10-2023,5,0.000131937
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-10-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-10-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-10-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-10-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-10-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-10-2023,347,0.009156398
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-10-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-10-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-10-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-10-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-10-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-10-2023,46883,0.659339578
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-10-2023,6,8.44E-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-10-2023,4657,0.06549377
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-10-2023,21,0.000295334
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2023,377,0.005301944
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-10-2023,64,0.000900065
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-10-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2023,540,0.007594296
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-10-2023,2,2.81E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-10-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-10-2023,347,0.004880038
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-10-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-10-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-10-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-10-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-10-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-10-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-10-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2023,44,0.000618794
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-10-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2023,223,0.003136163
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-10-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-10-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-10-2023,181,0.002545495
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-10-2023,16,0.000225016
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-10-2023,3251,0.045720474
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-10-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-10-2023,1297,0.018240374
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-10-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-10-2023,353,0.004964419
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-10-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-10-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-10-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-10-2023,809,0.01137738
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-10-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-10-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-10-2023,13,0.419354839
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-10-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-10-2023,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-10-2023,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-10-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-10-2023,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-10-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-10-2023,106,0.076700434
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-10-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-10-2023,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-10-2023,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-10-2023,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-10-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-10-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-10-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-10-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-10-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-10-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-10-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-10-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-10-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-10-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-10-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-10-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-10-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-11-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-11-2023,131,0.082754264
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-11-2023,9,0.005685407
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-11-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-11-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-11-2023,30,0.018951358
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-11-2023,44,0.027795325
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-11-2023,44,0.027795325
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-11-2023,483,0.305116867
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-11-2023,106,0.066961466
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-11-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-11-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-11-2023,108,0.068224889
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-11-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-11-2023,18,0.011370815
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-11-2023,23,0.014529375
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-11-2023,186,0.117498421
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-11-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-11-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-11-2023,221,0.139608339
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-11-2023,191,0.12065698
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-11-2023,14,0.008843967
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-11-2023,12,0.007580543
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-11-2023,2,0.001263424
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-11-2023,123,0.077700569
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-11-2023,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-11-2023,33,0.020846494
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-11-2023,41,0.02590019
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-11-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-11-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-11-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-11-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-11-2023,117,0.612565445
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-11-2023,56,0.293193717
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-11-2023,23,0.120418848
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-11-2023,117,0.612565445
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-11-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-11-2023,4,0.020942408
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-11-2023,113,0.591623037
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-11-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-11-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-11-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-11-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-11-2023,61,0.577319588
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-11-2023,15,0.103092784
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-11-2023,61,0.577319588
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-11-2023,52,0.272251309
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-11-2023,64,0.335078534
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-11-2023,9,0.047120419
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-11-2023,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-11-2023,116,0.607329843
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-11-2023,15,0.078534031
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-11-2023,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-11-2023,116,0.607329843
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-11-2023,116,0.607329843
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-11-2023,116,0.607329843
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-11-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-11-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-11-2023,2,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-11-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-11-2023,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-11-2023,117,0.5625
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-11-2023,117,0.5625
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-11-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-11-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-11-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-11-2023,5,0.012953368
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-11-2023,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-11-2023,8,0.020725389
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-11-2023,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-11-2023,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-11-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-11-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-11-2023,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-11-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-11-2023,6,0.015544041
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-11-2023,12,0.031088083
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-11-2023,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-11-2023,0,0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-11-2023,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-11-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-11-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-11-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-11-2023,66,0.170984456
M8,Family Planning,8.17.1,Complications following male sterilization,01-11-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-11-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-11-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-11-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-11-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-11-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-11-2023,15,0.038860104
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-11-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-11-2023,116,0.613756614
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-11-2023,116,0.613756614
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-11-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-11-2023,33,0.174603175
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-11-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-11-2023,116,0.613756614
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-11-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-11-2023,33,0.174603175
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-11-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-11-2023,116,0.613756614
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-11-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-11-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-11-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-11-2023,33,0.174603175
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-11-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-11-2023,30,0.158730159
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-11-2023,35,0.185185185
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-11-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-11-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-11-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-11-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-11-2023,6,0.031746032
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-11-2023,14,0.074074074
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-11-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-11-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-11-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-11-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-11-2023,4,0.021164021
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-11-2023,3,0.015873016
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-11-2023,1,0.005291005
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-11-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-11-2023,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-11-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-11-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-11-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-11-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-11-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-11-2023,9,0.047619048
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-11-2023,3,0.015873016
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-11-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-11-2023,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-11-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-11-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-11-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-11-2023,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-11-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-11-2023,21,0.177966102
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-11-2023,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-11-2023,6,0.050847458
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-11-2023,104,0.390977444
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-11-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-11-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-11-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-11-2023,51,0.191729323
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-11-2023,2,0.007518797
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-11-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-11-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-11-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-11-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-11-2023,7,0.026315789
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-11-2023,1,0.003759398
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-11-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-11-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-11-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-11-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-11-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-11-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-11-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-11-2023,16,0.126984127
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-11-2023,8,0.063492063
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-11-2023,8,0.063492063
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-11-2023,4,0.031746032
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-11-2023,16,0.126984127
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-11-2023,8,0.063492063
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-11-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-11-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-11-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-11-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-11-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-11-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-11-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-11-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-11-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-11-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-11-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-11-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-11-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-11-2023,6,0.6
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-11-2023,6,0.6
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-11-2023,6,0.6
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-11-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-11-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-11-2023,943,0.024883236
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-11-2023,851,0.022455603
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-11-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-11-2023,261,0.006887089
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-11-2023,298,0.007863419
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-11-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-11-2023,1602,0.042272475
M14,Patient Services,14.1.8,Outpatient - Dental,01-11-2023,969,0.025569306
M14,Patient Services,14.1.9,Outpatient - ENT ,01-11-2023,1182,0.031189804
M14,Patient Services,14.1.10,Outpatients- Asthma,01-11-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-11-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-11-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-11-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-11-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-11-2023,511,0.013483917
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-11-2023,0,0
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-11-2023,201,0.00530385
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-11-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-11-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-11-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-11-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-11-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-11-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-11-2023,606,0.015990712
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-11-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-11-2023,22180,0.585270602
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-11-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-11-2023,111,0.002928992
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-11-2023,889,0.023458321
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-11-2023,85,0.002242922
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-11-2023,970,0.025595694
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-11-2023,248,0.006544054
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-11-2023,110,0.002902604
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-11-2023,835,0.022033406
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-11-2023,78,0.00205821
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-11-2023,901,0.023774969
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-11-2023,237,0.006253793
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-11-2023,0,0
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-11-2023,3,7.92E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-11-2023,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-11-2023,0,0
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-11-2023,3,7.92E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-11-2023,1,2.64E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-11-2023,14,0.000369422
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-11-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-11-2023,4,0.000105549
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-11-2023,12,0.000316648
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-11-2023,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-11-2023,4,0.000105549
M14,Patient Services,14.3.6,Day Care Admissions,01-11-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-11-2023,2,5.28E-05
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-11-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-11-2023,266,0.007019025
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-11-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-11-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-11-2023,2,5.28E-05
M14,Patient Services,14.4.2,Inpatient - Dengue,01-11-2023,110,0.002902604
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-11-2023,2,5.28E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-11-2023,28,0.000738845
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-11-2023,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-11-2023,6,0.000158324
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-11-2023,6,0.000158324
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-11-2023,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-11-2023,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-11-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-11-2023,2028,0.053513471
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-11-2023,1380,0.036414492
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-11-2023,39,0.001029105
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-11-2023,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-11-2023,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-11-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-11-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-11-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-11-2023,6,0.000158324
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-11-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-11-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-11-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-11-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-11-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-11-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-11-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-11-2023,2,5.28E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-11-2023,73,0.001926274
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-11-2023,19,0.000501359
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-11-2023,0,0
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-11-2023,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-11-2023,88,0.002322084
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-11-2023,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-11-2023,8,0.000211099
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-11-2023,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-11-2023,10540,0.278122279
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-11-2023,57,0.001504077
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-11-2023,25,0.000659683
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-11-2023,24,0.000633296
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-11-2023,5,0.000131937
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-11-2023,3,7.92E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-11-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-11-2023,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-11-2023,29,0.000765232
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-11-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-11-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-11-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-11-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-11-2023,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-11-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-11-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-11-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-11-2023,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-11-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-11-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-11-2023,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-11-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-11-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-11-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-11-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-11-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-11-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-11-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-11-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-11-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-11-2023,270,0.007124575
M14,Patient Services,14.21,Total number of blood units issued in month,01-11-2023,270,0.007124575
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-11-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-11-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-11-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-11-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-11-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-11-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-11-2023,736,0.019421062
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-11-2023,661,0.017442014
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-11-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-11-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-11-2023,1,2.64E-05
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-11-2023,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-11-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-11-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-11-2023,1,2.64E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-11-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-11-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-11-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-11-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-11-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-11-2023,483,0.012745072
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-11-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-11-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-11-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-11-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-11-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-11-2023,45663,0.642182094
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-11-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-11-2023,3910,0.054988327
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-11-2023,67,0.000942255
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-11-2023,318,0.004472196
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-11-2023,8,0.000112508
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-11-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-11-2023,532,0.007481788
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-11-2023,5,7.03E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-11-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-11-2023,483,0.006792676
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-11-2023,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-11-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-11-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-11-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-11-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-11-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-11-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-11-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-11-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-11-2023,4,5.63E-05
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-11-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-11-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-11-2023,195,0.002742385
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-11-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-11-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-11-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-11-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-11-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-11-2023,13,0.000182826
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-11-2023,13,0.000182826
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-11-2023,2881,0.040516975
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-11-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-11-2023,1442,0.020279583
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-11-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-11-2023,359,0.0050488
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-11-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-11-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-11-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-11-2023,612,0.008606869
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-11-2023,11,0.35483871
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-11-2023,2,0.064516129
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-11-2023,31,1
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-11-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-11-2023,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-11-2023,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-11-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-11-2023,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-11-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-11-2023,164,0.118668596
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-11-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-11-2023,6,0.004341534
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-11-2023,6,0.004341534
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-11-2023,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-11-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-11-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-11-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-11-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-11-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-11-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-11-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-11-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-11-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-11-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-11-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-11-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-11-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-12-2023,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-12-2023,121,0.076437145
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-12-2023,7,0.004421984
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-12-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-12-2023,4,0.002526848
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-12-2023,41,0.02590019
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-12-2023,102,0.064434618
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-12-2023,182,0.114971573
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-12-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-12-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-12-2023,115,0.072646873
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-12-2023,23,0.014529375
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-12-2023,14,0.008843967
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-12-2023,24,0.015161087
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-12-2023,102,0.064434618
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-12-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-12-2023,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-12-2023,103,0.06506633
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-12-2023,101,0.063802906
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-12-2023,10,0.006317119
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-12-2023,8,0.005053696
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-12-2023,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-12-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-12-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-12-2023,105,0.066329754
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-12-2023,1,0.000631712
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-12-2023,35,0.022109918
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-12-2023,41,0.02590019
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-12-2023,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-12-2023,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-12-2023,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-12-2023,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-12-2023,137,0.717277487
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-12-2023,62,0.32460733
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-12-2023,27,0.141361257
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-12-2023,137,0.717277487
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-12-2023,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-12-2023,4,0.020942408
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-12-2023,133,0.696335079
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-12-2023,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-12-2023,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-12-2023,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-12-2023,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-12-2023,75,0.721649485
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-12-2023,25,0.206185567
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-12-2023,75,0.721649485
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-12-2023,77,0.403141361
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-12-2023,57,0.298429319
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-12-2023,13,0.068062827
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-12-2023,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-12-2023,134,0.701570681
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-12-2023,28,0.146596859
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-12-2023,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-12-2023,134,0.701570681
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-12-2023,134,0.701570681
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-12-2023,134,0.701570681
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-12-2023,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-12-2023,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-12-2023,4,0.08
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-12-2023,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-12-2023,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-12-2023,208,1
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-12-2023,208,1
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-12-2023,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-12-2023,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-12-2023,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-12-2023,7,0.018134715
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-12-2023,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-12-2023,5,0.012953368
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-12-2023,1,0.002590674
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-12-2023,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-12-2023,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-12-2023,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-12-2023,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-12-2023,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-12-2023,8,0.020725389
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-12-2023,12,0.031088083
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-12-2023,2,0.005181347
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-12-2023,4,0.010362694
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-12-2023,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-12-2023,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-12-2023,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-12-2023,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-12-2023,95,0.24611399
M8,Family Planning,8.17.1,Complications following male sterilization,01-12-2023,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-12-2023,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-12-2023,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-12-2023,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-12-2023,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-12-2023,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-12-2023,8,0.020725389
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-12-2023,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-12-2023,134,0.708994709
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-12-2023,134,0.708994709
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-12-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-12-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-12-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-12-2023,134,0.708994709
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-12-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-12-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-12-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-12-2023,134,0.708994709
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-12-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-12-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-12-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-12-2023,22,0.116402116
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-12-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-12-2023,27,0.142857143
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-12-2023,29,0.153439153
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-12-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-12-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-12-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-12-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-12-2023,13,0.068783069
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-12-2023,7,0.037037037
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-12-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-12-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-12-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-12-2023,12,0.063492063
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-12-2023,12,0.063492063
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-12-2023,12,0.063492063
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-12-2023,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-12-2023,2,0.010582011
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-12-2023,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-12-2023,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-12-2023,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-12-2023,8,0.042328042
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-12-2023,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-12-2023,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-12-2023,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-12-2023,20,0.105820106
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-12-2023,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-12-2023,14,0.118644068
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-12-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-12-2023,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-12-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-12-2023,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-12-2023,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-12-2023,34,0.288135593
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-12-2023,16,0.13559322
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-12-2023,3,0.025423729
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-12-2023,117,0.439849624
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-12-2023,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-12-2023,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-12-2023,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-12-2023,37,0.139097744
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-12-2023,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-12-2023,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-12-2023,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-12-2023,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-12-2023,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-12-2023,5,0.018796992
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-12-2023,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-12-2023,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-12-2023,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-12-2023,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-12-2023,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-12-2023,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-12-2023,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-12-2023,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-12-2023,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-12-2023,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-12-2023,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-12-2023,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-12-2023,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-12-2023,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-12-2023,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-12-2023,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-12-2023,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-12-2023,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-12-2023,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-12-2023,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-12-2023,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-12-2023,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-12-2023,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-12-2023,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-12-2023,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-12-2023,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-12-2023,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-12-2023,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-12-2023,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-12-2023,900,0.023748582
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-12-2023,821,0.021663984
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-12-2023,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-12-2023,1,2.64E-05
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-12-2023,747,0.019711323
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-12-2023,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-12-2023,2152,0.056785498
M14,Patient Services,14.1.8,Outpatient - Dental,01-12-2023,1282,0.033828535
M14,Patient Services,14.1.9,Outpatient - ENT ,01-12-2023,1954,0.05156081
M14,Patient Services,14.1.10,Outpatients- Asthma,01-12-2023,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-12-2023,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-12-2023,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-12-2023,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-12-2023,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-12-2023,150,0.003958097
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-12-2023,155,0.004090034
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-12-2023,1250,0.032984141
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-12-2023,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-12-2023,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-12-2023,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-12-2023,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-12-2023,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-12-2023,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-12-2023,713,0.018814154
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-12-2023,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-12-2023,33635,0.887537272
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-12-2023,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-12-2023,229,0.006042695
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-12-2023,896,0.023643032
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-12-2023,160,0.00422197
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-12-2023,823,0.021716759
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-12-2023,354,0.009341109
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-12-2023,210,0.005541336
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-12-2023,910,0.024012455
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-12-2023,172,0.004538618
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-12-2023,832,0.021954244
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-12-2023,355,0.009367496
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-12-2023,3,7.92E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-12-2023,4,0.000105549
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-12-2023,2,5.28E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-12-2023,1,2.64E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-12-2023,1,2.64E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-12-2023,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-12-2023,0,0
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-12-2023,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-12-2023,0,0
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-12-2023,0,0
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-12-2023,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-12-2023,4,0.000105549
M14,Patient Services,14.3.6,Day Care Admissions,01-12-2023,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-12-2023,45,0.001187429
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-12-2023,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-12-2023,277,0.007309286
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-12-2023,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-12-2023,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-12-2023,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-12-2023,110,0.002902604
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-12-2023,4,0.000105549
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-12-2023,60,0.001583239
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-12-2023,8,0.000211099
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-12-2023,15,0.00039581
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-12-2023,0,0
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-12-2023,75,0.001979048
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-12-2023,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-12-2023,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-12-2023,2537,0.066944613
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-12-2023,915,0.024144391
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-12-2023,112,0.002955379
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-12-2023,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-12-2023,1,2.64E-05
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-12-2023,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-12-2023,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-12-2023,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-12-2023,12,0.000316648
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-12-2023,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-12-2023,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-12-2023,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-12-2023,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-12-2023,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-12-2023,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-12-2023,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-12-2023,2,5.28E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-12-2023,462,0.012190939
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-12-2023,14,0.000369422
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-12-2023,323,0.008523102
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-12-2023,3,7.92E-05
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-12-2023,148,0.003905322
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-12-2023,10,0.000263873
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-12-2023,300,0.007916194
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-12-2023,300,0.007916194
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-12-2023,13005,0.343167005
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-12-2023,62,0.001636013
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-12-2023,40,0.001055493
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-12-2023,14,0.000369422
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-12-2023,4,0.000105549
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-12-2023,4,0.000105549
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-12-2023,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-12-2023,1,2.64E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-12-2023,13,0.000343035
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-12-2023,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-12-2023,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-12-2023,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-12-2023,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-12-2023,3,7.92E-05
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-12-2023,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-12-2023,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-12-2023,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-12-2023,3,7.92E-05
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-12-2023,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-12-2023,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-12-2023,1,2.64E-05
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-12-2023,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-12-2023,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-12-2023,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-12-2023,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-12-2023,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-12-2023,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-12-2023,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-12-2023,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-12-2023,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-12-2023,300,0.007916194
M14,Patient Services,14.21,Total number of blood units issued in month,01-12-2023,300,0.007916194
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-12-2023,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-12-2023,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-12-2023,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-12-2023,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-12-2023,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-12-2023,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-12-2023,967,0.025516532
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-12-2023,866,0.022851413
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-12-2023,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-12-2023,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-12-2023,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-12-2023,13,0.000343035
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-12-2023,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-12-2023,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-12-2023,3,7.92E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-12-2023,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-12-2023,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-12-2023,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-12-2023,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-12-2023,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-12-2023,502,0.013246431
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-12-2023,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-12-2023,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-12-2023,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-12-2023,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-12-2023,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-12-2023,45015,0.633068939
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-12-2023,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-12-2023,3938,0.055382106
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-12-2023,64,0.000900065
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-12-2023,435,0.006117627
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-12-2023,4,5.63E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-12-2023,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-12-2023,502,0.007059882
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-12-2023,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-12-2023,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-12-2023,528,0.007425534
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-12-2023,3,4.22E-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-12-2023,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-12-2023,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-12-2023,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-12-2023,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-12-2023,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-12-2023,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-12-2023,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-12-2023,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-12-2023,42,0.000590667
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-12-2023,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-12-2023,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-12-2023,238,0.003347116
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-12-2023,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-12-2023,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-12-2023,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-12-2023,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-12-2023,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-12-2023,95,0.001336034
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-12-2023,3,4.22E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-12-2023,3197,0.044961044
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-12-2023,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-12-2023,1310,0.018423199
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-12-2023,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-12-2023,419,0.005892611
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-12-2023,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-12-2023,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-12-2023,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-12-2023,700,0.009844458
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-12-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-12-2023,1,0.032258065
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-12-2023,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-12-2023,2,0.064516129
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-12-2023,13,0.419354839
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-12-2023,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-12-2023,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-12-2023,0,0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-12-2023,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-12-2023,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-12-2023,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-12-2023,240,0.17366136
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-12-2023,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-12-2023,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-12-2023,2,0.001447178
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-12-2023,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-12-2023,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-12-2023,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-12-2023,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-12-2023,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-12-2023,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-12-2023,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-12-2023,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-12-2023,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-12-2023,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-12-2023,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-12-2023,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-12-2023,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-12-2023,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-01-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-01-2024,155,0.097915351
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-01-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-01-2024,7,0.004421984
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-01-2024,3,0.001895136
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-01-2024,24,0.015161087
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-01-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-01-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-01-2024,38,0.024005054
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-01-2024,73,0.046114972
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-01-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-01-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-01-2024,118,0.074542009
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-01-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-01-2024,3,0.001895136
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-01-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-01-2024,134,0.0846494
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-01-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-01-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-01-2024,134,0.0846494
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-01-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-01-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-01-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-01-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-01-2024,42,0.026531901
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-01-2024,30,0.018951358
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-01-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-01-2024,8,0.005053696
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-01-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-01-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-01-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-01-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-01-2024,113,0.591623037
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-01-2024,60,0.314136126
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-01-2024,30,0.157068063
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-01-2024,113,0.591623037
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-01-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-01-2024,19,0.09947644
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-01-2024,94,0.492146597
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-01-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-01-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-01-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-01-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-01-2024,53,0.494845361
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-01-2024,10,0.051546392
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-01-2024,53,0.494845361
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-01-2024,57,0.298429319
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-01-2024,56,0.293193717
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-01-2024,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-01-2024,113,0.591623037
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-01-2024,6,0.031413613
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-01-2024,113,0.591623037
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-01-2024,113,0.591623037
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-01-2024,113,0.591623037
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-01-2024,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-01-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-01-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-01-2024,12,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-01-2024,2,0.009615385
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-01-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-01-2024,0,0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-01-2024,0,0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-01-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-01-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-01-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-01-2024,8,0.020725389
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-01-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-01-2024,12,0.031088083
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-01-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-01-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-01-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-01-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-01-2024,6,0.015544041
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-01-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-01-2024,4,0.010362694
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-01-2024,2,0.005181347
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-01-2024,1,0.002590674
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-01-2024,1,0.002590674
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-01-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-01-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-01-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-01-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-01-2024,0,0
M8,Family Planning,8.17.1,Complications following male sterilization,01-01-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-01-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-01-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-01-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-01-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-01-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-01-2024,16,0.041450777
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-01-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-01-2024,113,0.597883598
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-01-2024,113,0.597883598
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-01-2024,45,0.238095238
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-01-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-01-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-01-2024,113,0.597883598
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-01-2024,45,0.238095238
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-01-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-01-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-01-2024,113,0.597883598
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-01-2024,45,0.238095238
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-01-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-01-2024,45,0.238095238
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-01-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-01-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-01-2024,45,0.238095238
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-01-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-01-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-01-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-01-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-01-2024,6,0.031746032
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-01-2024,6,0.031746032
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-01-2024,12,0.063492063
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-01-2024,12,0.063492063
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-01-2024,12,0.063492063
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-01-2024,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-01-2024,3,0.015873016
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-01-2024,3,0.015873016
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-01-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-01-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-01-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-01-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-01-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-01-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-01-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-01-2024,5,0.042372881
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-01-2024,5,0.042372881
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-01-2024,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-01-2024,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-01-2024,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-01-2024,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-01-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-01-2024,15,0.127118644
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-01-2024,17,0.144067797
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-01-2024,8,0.06779661
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-01-2024,96,0.360902256
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-01-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-01-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-01-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-01-2024,33,0.12406015
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-01-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-01-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-01-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-01-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-01-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-01-2024,40,0.15037594
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-01-2024,22,0.082706767
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-01-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-01-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-01-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-01-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-01-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-01-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-01-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-01-2024,16,0.126984127
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-01-2024,7,0.055555556
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-01-2024,16,0.126984127
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-01-2024,7,0.055555556
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-01-2024,16,0.126984127
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-01-2024,6,0.047619048
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-01-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-01-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-01-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-01-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-01-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-01-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-01-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-01-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-01-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-01-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-01-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-01-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-01-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-01-2024,1,0.1
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-01-2024,1,0.1
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-01-2024,1,0.1
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-01-2024,1,0.1
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-01-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-01-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-01-2024,800,0.02110985
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-01-2024,701,0.018497506
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-01-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-01-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-01-2024,878,0.023168061
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-01-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-01-2024,2516,0.066390479
M14,Patient Services,14.1.8,Outpatient - Dental,01-01-2024,1367,0.036071457
M14,Patient Services,14.1.9,Outpatient - ENT ,01-01-2024,2212,0.058368736
M14,Patient Services,14.1.10,Outpatients- Asthma,01-01-2024,18,0.000474972
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-01-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-01-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-01-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-01-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-01-2024,26,0.00068607
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-01-2024,350,0.00923556
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-01-2024,1267,0.033432726
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-01-2024,4,0.000105549
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-01-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-01-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-01-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-01-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-01-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-01-2024,774,0.02042378
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-01-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-01-2024,37897,1
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-01-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-01-2024,160,0.00422197
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-01-2024,857,0.022613927
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-01-2024,173,0.004565005
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-01-2024,911,0.024038842
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-01-2024,374,0.009868855
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-01-2024,173,0.004565005
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-01-2024,851,0.022455603
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-01-2024,158,0.004169195
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-01-2024,891,0.023511096
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-01-2024,374,0.009868855
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-01-2024,0,0
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-01-2024,0,0
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-01-2024,0,0
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-01-2024,0,0
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-01-2024,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-01-2024,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-01-2024,0,0
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-01-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-01-2024,0,0
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-01-2024,0,0
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-01-2024,4,0.000105549
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-01-2024,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-01-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-01-2024,52,0.00137214
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-01-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-01-2024,268,0.0070718
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-01-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-01-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-01-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-01-2024,65,0.001715175
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-01-2024,2,5.28E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-01-2024,50,0.001319366
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-01-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-01-2024,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-01-2024,25,0.000659683
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-01-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-01-2024,101,0.002665119
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-01-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-01-2024,1534,0.040478138
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-01-2024,570,0.015040768
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-01-2024,110,0.002902604
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-01-2024,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-01-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-01-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-01-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-01-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-01-2024,7,0.000184711
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-01-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-01-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-01-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-01-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-01-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-01-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-01-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-01-2024,3,7.92E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-01-2024,442,0.011663192
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-01-2024,17,0.000448584
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-01-2024,293,0.007731483
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-01-2024,2,5.28E-05
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-01-2024,134,0.0035359
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-01-2024,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-01-2024,187,0.004934428
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-01-2024,187,0.004934428
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-01-2024,12914,0.34076576
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-01-2024,49,0.001292978
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-01-2024,26,0.00068607
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-01-2024,18,0.000474972
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-01-2024,1,2.64E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-01-2024,4,0.000105549
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-01-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-01-2024,2,5.28E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-01-2024,47,0.001240204
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-01-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-01-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-01-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-01-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-01-2024,1,2.64E-05
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-01-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-01-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-01-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-01-2024,1,2.64E-05
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-01-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-01-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-01-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-01-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-01-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-01-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-01-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-01-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-01-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-01-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-01-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-01-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-01-2024,187,0.004934428
M14,Patient Services,14.21,Total number of blood units issued in month,01-01-2024,187,0.004934428
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-01-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-01-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-01-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-01-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-01-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-01-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-01-2024,9,0.000237486
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-01-2024,929,0.024513814
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-01-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-01-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-01-2024,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-01-2024,1,2.64E-05
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-01-2024,1064,0.028076101
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-01-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-01-2024,3,7.92E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-01-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-01-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-01-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-01-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-01-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-01-2024,434,0.011452094
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-01-2024,1,2.64E-05
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-01-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-01-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-01-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-01-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-01-2024,45403,0.638525582
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-01-2024,1,1.41E-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-01-2024,3619,0.050895846
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-01-2024,17,0.00023908
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-01-2024,460,0.006469215
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-01-2024,7,9.84E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-01-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-01-2024,591,0.008311535
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-01-2024,5,7.03E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-01-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-01-2024,434,0.006103564
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-01-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-01-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-01-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-01-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-01-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-01-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-01-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-01-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-01-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-01-2024,39,0.000548477
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-01-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-01-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-01-2024,269,0.003783084
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-01-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-01-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-01-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-01-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-01-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-01-2024,124,0.001743875
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-01-2024,3,4.22E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-01-2024,2986,0.041993643
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-01-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-01-2024,1361,0.019140438
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-01-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-01-2024,368,0.005175372
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-01-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-01-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-01-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-01-2024,800,0.011250809
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-01-2024,10,0.322580645
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-01-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-01-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-01-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-01-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-01-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-01-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-01-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-01-2024,2,0.001447178
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-01-2024,1382,1
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-01-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-01-2024,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-01-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-01-2024,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-01-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-01-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-01-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-01-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-01-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-01-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-01-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-01-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-01-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-01-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-01-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-01-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-01-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-02-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-02-2024,180,0.113708149
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-02-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-02-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-02-2024,7,0.004421984
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-02-2024,24,0.015161087
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-02-2024,45,0.028427037
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-02-2024,45,0.028427037
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-02-2024,28,0.017687934
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-02-2024,42,0.026531901
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-02-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-02-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-02-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-02-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-02-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-02-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-02-2024,38,0.024005054
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-02-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-02-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-02-2024,39,0.024636766
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-02-2024,52,0.032849021
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-02-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-02-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-02-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-02-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-02-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-02-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-02-2024,4,0.002526848
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-02-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-02-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-02-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-02-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-02-2024,128,0.670157068
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-02-2024,76,0.397905759
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-02-2024,42,0.219895288
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-02-2024,128,0.670157068
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-02-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-02-2024,0,0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-02-2024,14,0.073298429
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-02-2024,114,0.596858639
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-02-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-02-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-02-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-02-2024,52,0.484536082
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-02-2024,8,0.030927835
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-02-2024,52,0.484536082
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-02-2024,69,0.361256545
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-02-2024,57,0.298429319
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-02-2024,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-02-2024,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-02-2024,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-02-2024,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-02-2024,126,0.659685864
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-02-2024,19,0.09947644
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-02-2024,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-02-2024,126,0.659685864
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-02-2024,126,0.659685864
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-02-2024,126,0.659685864
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-02-2024,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-02-2024,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-02-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-02-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-02-2024,12,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-02-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-02-2024,201,0.966346154
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-02-2024,201,0.966346154
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-02-2024,201,0.966346154
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-02-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-02-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-02-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-02-2024,5,0.012953368
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-02-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-02-2024,6,0.015544041
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-02-2024,1,0.002590674
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-02-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-02-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-02-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-02-2024,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-02-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-02-2024,4,0.010362694
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-02-2024,2,0.005181347
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-02-2024,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-02-2024,2,0.005181347
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-02-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-02-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-02-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-02-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-02-2024,66,0.170984456
M8,Family Planning,8.17.1,Complications following male sterilization,01-02-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-02-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-02-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-02-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-02-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-02-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-02-2024,12,0.031088083
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-02-2024,126,0.666666667
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-02-2024,126,0.666666667
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-02-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-02-2024,126,0.666666667
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-02-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-02-2024,126,0.666666667
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-02-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-02-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-02-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-02-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-02-2024,35,0.185185185
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-02-2024,35,0.185185185
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-02-2024,35,0.185185185
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-02-2024,10,0.052910053
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-02-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-02-2024,4,0.021164021
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-02-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-02-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-02-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-02-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-02-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-02-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-02-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-02-2024,9,0.047619048
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-02-2024,19,0.161016949
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-02-2024,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-02-2024,5,0.042372881
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-02-2024,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-02-2024,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-02-2024,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-02-2024,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-02-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-02-2024,23,0.194915254
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-02-2024,19,0.161016949
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-02-2024,9,0.076271186
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-02-2024,85,0.319548872
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-02-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-02-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-02-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-02-2024,82,0.308270677
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-02-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-02-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-02-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-02-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-02-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-02-2024,14,0.052631579
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-02-2024,2,0.007518797
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-02-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-02-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-02-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-02-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-02-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-02-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-02-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-02-2024,126,1
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-02-2024,119,0.944444444
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-02-2024,126,1
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-02-2024,119,0.944444444
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-02-2024,126,1
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-02-2024,119,0.944444444
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-02-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-02-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-02-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-02-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-02-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-02-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-02-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-02-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-02-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-02-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-02-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-02-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-02-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-02-2024,1,0.1
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-02-2024,2,0.2
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-02-2024,2,0.2
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-02-2024,2,0.2
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-02-2024,2,0.2
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-02-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-02-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-02-2024,750,0.019790485
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-02-2024,655,0.01728369
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-02-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-02-2024,1,2.64E-05
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-02-2024,907,0.023933293
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-02-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-02-2024,2452,0.064701691
M14,Patient Services,14.1.8,Outpatient - Dental,01-02-2024,1562,0.041216983
M14,Patient Services,14.1.9,Outpatient - ENT ,01-02-2024,2278,0.060110299
M14,Patient Services,14.1.10,Outpatients- Asthma,01-02-2024,29,0.000765232
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-02-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-02-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-02-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-02-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-02-2024,22,0.000580521
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-02-2024,398,0.010502151
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-02-2024,1387,0.036599203
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-02-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-02-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-02-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-02-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-02-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-02-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-02-2024,768,0.020265456
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-02-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-02-2024,37385,0.986489696
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-02-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-02-2024,196,0.005171913
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-02-2024,799,0.021083463
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-02-2024,143,0.003773386
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-02-2024,797,0.021030688
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-02-2024,388,0.010238277
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-02-2024,201,0.00530385
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-02-2024,782,0.020634879
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-02-2024,151,0.003984484
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-02-2024,813,0.021452885
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-02-2024,381,0.010053566
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-02-2024,1,2.64E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-02-2024,3,7.92E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-02-2024,2,5.28E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-02-2024,1,2.64E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-02-2024,2,5.28E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-02-2024,1,2.64E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-02-2024,7,0.000184711
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-02-2024,1,2.64E-05
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-02-2024,6,0.000158324
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-02-2024,8,0.000211099
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-02-2024,8,0.000211099
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-02-2024,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-02-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-02-2024,48,0.001266591
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-02-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-02-2024,252,0.006649603
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-02-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-02-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-02-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-02-2024,68,0.001794337
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-02-2024,1,2.64E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-02-2024,45,0.001187429
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-02-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-02-2024,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-02-2024,30,0.000791619
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-02-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-02-2024,131,0.003456738
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-02-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-02-2024,1390,0.036678365
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-02-2024,420,0.011082671
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-02-2024,92,0.002427633
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-02-2024,0,0
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-02-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-02-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-02-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-02-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-02-2024,4,0.000105549
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-02-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-02-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-02-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-02-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-02-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-02-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-02-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-02-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-02-2024,498,0.013140882
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-02-2024,15,0.00039581
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-02-2024,318,0.008391166
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-02-2024,2,5.28E-05
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-02-2024,130,0.003430351
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-02-2024,3,7.92E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-02-2024,169,0.004459456
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-02-2024,169,0.004459456
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-02-2024,12268,0.323719556
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-02-2024,60,0.001583239
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-02-2024,40,0.001055493
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-02-2024,20,0.000527746
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-02-2024,4,0.000105549
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-02-2024,0,0
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-02-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-02-2024,1,2.64E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-02-2024,10,0.000263873
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-02-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-02-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-02-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-02-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-02-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-02-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-02-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-02-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-02-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-02-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-02-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-02-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-02-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-02-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-02-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-02-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-02-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-02-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-02-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-02-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-02-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-02-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-02-2024,169,0.004459456
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-02-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-02-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-02-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-02-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-02-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-02-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-02-2024,0,0
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-02-2024,0,0
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-02-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-02-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-02-2024,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-02-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-02-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-02-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-02-2024,0,0
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-02-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-02-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-02-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-02-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-02-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-02-2024,382,0.010079954
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-02-2024,1,2.64E-05
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-02-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-02-2024,1,2.64E-05
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-02-2024,1,2.64E-05
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-02-2024,1,2.64E-05
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-02-2024,57804,0.812927179
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-02-2024,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-02-2024,4939,0.06945968
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-02-2024,22,0.000309397
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-02-2024,534,0.007509915
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-02-2024,2,2.81E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-02-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-02-2024,637,0.008958456
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-02-2024,1,1.41E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-02-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-02-2024,382,0.005372261
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-02-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-02-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-02-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-02-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-02-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-02-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-02-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-02-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-02-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-02-2024,6,8.44E-05
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-02-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-02-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-02-2024,278,0.003909656
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-02-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-02-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-02-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-02-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-02-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-02-2024,113,0.001589177
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-02-2024,13,0.000182826
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-02-2024,2995,0.042120215
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-02-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-02-2024,1299,0.018268501
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-02-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-02-2024,444,0.006244199
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-02-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-02-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-02-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-02-2024,1016,0.014288527
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-02-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-02-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-02-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-02-2024,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-02-2024,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-02-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-02-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-02-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-02-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-02-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-02-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-02-2024,185,0.133863965
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-02-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-02-2024,6,0.004341534
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-02-2024,2,0.001447178
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-02-2024,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-02-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-02-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-02-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-02-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-02-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-02-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-02-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-02-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-02-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-02-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-02-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-02-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-02-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-03-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-03-2024,1397,0.882501579
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-03-2024,11,0.006948831
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-03-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-03-2024,5,0.00315856
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-03-2024,31,0.01958307
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-03-2024,52,0.032849021
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-03-2024,52,0.032849021
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-03-2024,451,0.284902085
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-03-2024,132,0.083385976
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-03-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-03-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-03-2024,147,0.092861655
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-03-2024,18,0.011370815
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-03-2024,451,0.284902085
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-03-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-03-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-03-2024,200,0.126342388
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-03-2024,200,0.126342388
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-03-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-03-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-03-2024,132,0.083385976
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-03-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-03-2024,41,0.02590019
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-03-2024,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-03-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-03-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-03-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-03-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-03-2024,140,0.732984293
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-03-2024,75,0.392670157
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-03-2024,33,0.172774869
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-03-2024,140,0.732984293
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-03-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-03-2024,6,0.031413613
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-03-2024,134,0.701570681
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-03-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-03-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-03-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-03-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-03-2024,65,0.618556701
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-03-2024,16,0.113402062
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-03-2024,65,0.618556701
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-03-2024,72,0.376963351
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-03-2024,66,0.345549738
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-03-2024,18,0.094240838
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-03-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-03-2024,138,0.722513089
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-03-2024,22,0.115183246
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-03-2024,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-03-2024,138,0.722513089
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-03-2024,138,0.722513089
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-03-2024,138,0.722513089
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-03-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-03-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-03-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-03-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-03-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-03-2024,0,0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-03-2024,0,0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-03-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-03-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-03-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-03-2024,11,0.028497409
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-03-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-03-2024,12,0.031088083
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-03-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-03-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-03-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-03-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-03-2024,8,0.020725389
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-03-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-03-2024,6,0.015544041
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-03-2024,7,0.018134715
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-03-2024,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-03-2024,4,0.010362694
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-03-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-03-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-03-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-03-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-03-2024,78,0.202072539
M8,Family Planning,8.17.1,Complications following male sterilization,01-03-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-03-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-03-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-03-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-03-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-03-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-03-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-03-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-03-2024,138,0.73015873
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-03-2024,138,0.73015873
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-03-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-03-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-03-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-03-2024,138,0.73015873
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-03-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-03-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-03-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-03-2024,138,0.73015873
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-03-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-03-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-03-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-03-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-03-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-03-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-03-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-03-2024,16,0.084656085
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-03-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-03-2024,16,0.084656085
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-03-2024,16,0.084656085
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-03-2024,20,0.105820106
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-03-2024,11,0.058201058
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-03-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-03-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-03-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-03-2024,3,0.015873016
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-03-2024,3,0.015873016
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-03-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-03-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-03-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-03-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-03-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-03-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-03-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-03-2024,7,0.037037037
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-03-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-03-2024,10,0.052910053
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-03-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-03-2024,11,0.058201058
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-03-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-03-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-03-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-03-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-03-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-03-2024,16,0.084656085
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-03-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-03-2024,12,0.101694915
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-03-2024,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-03-2024,2,0.016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-03-2024,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-03-2024,21,0.177966102
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-03-2024,21,0.177966102
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-03-2024,21,0.177966102
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-03-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-03-2024,22,0.186440678
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-03-2024,12,0.101694915
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-03-2024,21,0.177966102
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-03-2024,110,0.413533835
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-03-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-03-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-03-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-03-2024,22,0.082706767
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-03-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-03-2024,1,0.003759398
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-03-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-03-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-03-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-03-2024,3,0.011278195
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-03-2024,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-03-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-03-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-03-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-03-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-03-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-03-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-03-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-03-2024,20,0.158730159
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-03-2024,11,0.087301587
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-03-2024,16,0.126984127
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-03-2024,8,0.063492063
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-03-2024,20,0.158730159
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-03-2024,11,0.087301587
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-03-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-03-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-03-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-03-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-03-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-03-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-03-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-03-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-03-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-03-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-03-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-03-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-03-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-03-2024,3,0.3
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-03-2024,3,0.3
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-03-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-03-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-03-2024,630,0.016624007
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-03-2024,560,0.014776895
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-03-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-03-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-03-2024,737,0.01944745
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-03-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-03-2024,2162,0.057049371
M14,Patient Services,14.1.8,Outpatient - Dental,01-03-2024,1480,0.039053223
M14,Patient Services,14.1.9,Outpatient - ENT ,01-03-2024,1944,0.051296936
M14,Patient Services,14.1.10,Outpatients- Asthma,01-03-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-03-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-03-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-03-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-03-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-03-2024,20,0.000527746
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-03-2024,328,0.008655039
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-03-2024,1240,0.032720268
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-03-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-03-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-03-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-03-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-03-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-03-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-03-2024,707,0.01865583
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-03-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-03-2024,33539,0.88500409
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-03-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-03-2024,167,0.004406681
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-03-2024,701,0.018497506
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-03-2024,121,0.003192865
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-03-2024,743,0.019605774
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-03-2024,353,0.009314721
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-03-2024,170,0.004485843
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-03-2024,761,0.020080745
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-03-2024,130,0.003430351
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-03-2024,791,0.020872365
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-03-2024,368,0.009710531
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-03-2024,3,7.92E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-03-2024,0,0
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-03-2024,5,0.000131937
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-03-2024,0,0
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-03-2024,2,5.28E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-03-2024,1,2.64E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-03-2024,12,0.000316648
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-03-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-03-2024,4,0.000105549
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-03-2024,7,0.000184711
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-03-2024,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-03-2024,2,5.28E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-03-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-03-2024,0,0
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-03-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-03-2024,285,0.007520384
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-03-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-03-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-03-2024,1,2.64E-05
M14,Patient Services,14.4.2,Inpatient - Dengue,01-03-2024,25,0.000659683
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-03-2024,2,5.28E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-03-2024,4,0.000105549
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-03-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-03-2024,19,0.000501359
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-03-2024,5,0.000131937
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-03-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-03-2024,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-03-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-03-2024,2645,0.069794443
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-03-2024,740,0.019526612
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-03-2024,83,0.002190147
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-03-2024,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-03-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-03-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-03-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-03-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-03-2024,9,0.000237486
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-03-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-03-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-03-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-03-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-03-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-03-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-03-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-03-2024,3,7.92E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-03-2024,491,0.012956171
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-03-2024,19,0.000501359
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-03-2024,281,0.007414835
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-03-2024,2,5.28E-05
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-03-2024,148,0.003905322
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-03-2024,3,7.92E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-03-2024,240,0.006332955
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-03-2024,240,0.006332955
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-03-2024,11486,0.303084677
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-03-2024,70,0.001847112
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-03-2024,43,0.001134654
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-03-2024,20,0.000527746
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-03-2024,6,0.000158324
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-03-2024,2,5.28E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-03-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-03-2024,1,2.64E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-03-2024,14,0.000369422
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-03-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-03-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-03-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-03-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-03-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-03-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-03-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-03-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-03-2024,8,0.000211099
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-03-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-03-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-03-2024,2,5.28E-05
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-03-2024,2,5.28E-05
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-03-2024,3,7.92E-05
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-03-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-03-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-03-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-03-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-03-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-03-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-03-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-03-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-03-2024,240,0.006332955
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-03-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-03-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-03-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-03-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-03-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-03-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-03-2024,1011,0.026677573
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-03-2024,877,0.023141673
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-03-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-03-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-03-2024,16,0.000422197
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-03-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-03-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-03-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-03-2024,2,5.28E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-03-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-03-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-03-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-03-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-03-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-03-2024,451,0.011900678
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-03-2024,1,2.64E-05
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-03-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-03-2024,1,2.64E-05
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-03-2024,1,2.64E-05
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-03-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-03-2024,55790,0.784603268
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-03-2024,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-03-2024,3982,0.0560009
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-03-2024,10,0.000140635
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-03-2024,415,0.005836357
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-03-2024,1,1.41E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-03-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-03-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-03-2024,601,0.00845217
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-03-2024,3,4.22E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-03-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-03-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-03-2024,451,0.006342643
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-03-2024,1,1.41E-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-03-2024,1,1.41E-05
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-03-2024,1,1.41E-05
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-03-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-03-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-03-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-03-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-03-2024,52,0.000731303
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-03-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-03-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-03-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-03-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-03-2024,8,0.000112508
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-03-2024,2,2.81E-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-03-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-03-2024,255,0.003586195
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-03-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-03-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-03-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-03-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-03-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-03-2024,70,0.000984446
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-03-2024,6,8.44E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-03-2024,2863,0.040263831
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-03-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-03-2024,1324,0.018620088
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-03-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-03-2024,476,0.006694231
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-03-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-03-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-03-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-03-2024,963,0.013543161
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-03-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-03-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-03-2024,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-03-2024,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-03-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-03-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-03-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-03-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-03-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-03-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-03-2024,198,0.143270622
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-03-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-03-2024,7,0.005065123
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-03-2024,7,0.005065123
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-03-2024,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-03-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-03-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-03-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-03-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-03-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-03-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-03-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-03-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-03-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-03-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-03-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-03-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-03-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-04-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-04-2024,881,0.556538219
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-04-2024,7,0.004421984
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-04-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-04-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-04-2024,34,0.021478206
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-04-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-04-2024,36,0.02274163
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-04-2024,36,0.02274163
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-04-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-04-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-04-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-04-2024,0,0
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-04-2024,0,0
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-04-2024,187,0.118130133
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-04-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-04-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-04-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-04-2024,48,0.030322173
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-04-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-04-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-04-2024,48,0.030322173
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-04-2024,82,0.051800379
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-04-2024,23,0.014529375
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-04-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-04-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-04-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-04-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-04-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-04-2024,8,0.005053696
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-04-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-04-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-04-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-04-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-04-2024,161,0.842931937
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-04-2024,86,0.45026178
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-04-2024,31,0.162303665
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-04-2024,161,0.842931937
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-04-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-04-2024,5,0.02617801
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-04-2024,156,0.816753927
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-04-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-04-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-04-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-04-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-04-2024,75,0.721649485
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-04-2024,32,0.278350515
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-04-2024,75,0.721649485
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-04-2024,94,0.492146597
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-04-2024,71,0.371727749
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-04-2024,11,0.057591623
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-04-2024,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-04-2024,165,0.863874346
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-04-2024,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-04-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-04-2024,165,0.863874346
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-04-2024,165,0.863874346
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-04-2024,165,0.863874346
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-04-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-04-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-04-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-04-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-04-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-04-2024,161,0.774038462
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-04-2024,161,0.774038462
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-04-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-04-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-04-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-04-2024,10,0.025906736
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-04-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-04-2024,13,0.033678756
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-04-2024,1,0.002590674
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-04-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-04-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-04-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-04-2024,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-04-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-04-2024,6,0.015544041
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-04-2024,2,0.005181347
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-04-2024,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-04-2024,4,0.010362694
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-04-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-04-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-04-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-04-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-04-2024,108,0.279792746
M8,Family Planning,8.17.1,Complications following male sterilization,01-04-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-04-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-04-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-04-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-04-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-04-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-04-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-04-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-04-2024,165,0.873015873
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-04-2024,165,0.873015873
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-04-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-04-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-04-2024,165,0.873015873
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-04-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-04-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-04-2024,165,0.873015873
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-04-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-04-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-04-2024,23,0.121693122
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-04-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-04-2024,11,0.058201058
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-04-2024,8,0.042328042
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-04-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-04-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-04-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-04-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-04-2024,6,0.031746032
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-04-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-04-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-04-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-04-2024,4,0.021164021
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-04-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-04-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-04-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-04-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-04-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-04-2024,12,0.063492063
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-04-2024,11,0.093220339
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-04-2024,7,0.059322034
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-04-2024,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-04-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-04-2024,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-04-2024,2,0.016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-04-2024,11,0.093220339
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-04-2024,86,0.323308271
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-04-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-04-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-04-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-04-2024,10,0.037593985
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-04-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-04-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-04-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-04-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-04-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-04-2024,12,0.045112782
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-04-2024,8,0.030075188
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-04-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-04-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-04-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-04-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-04-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-04-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-04-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-04-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-04-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-04-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-04-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-04-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-04-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-04-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-04-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-04-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-04-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-04-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-04-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-04-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-04-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-04-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-04-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-04-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-04-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-04-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-04-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-04-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-04-2024,550,0.014513022
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-04-2024,480,0.01266591
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-04-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-04-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-04-2024,285,0.007520384
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-04-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-04-2024,1320,0.034831253
M14,Patient Services,14.1.8,Outpatient - Dental,01-04-2024,834,0.022007019
M14,Patient Services,14.1.9,Outpatient - ENT ,01-04-2024,996,0.026281764
M14,Patient Services,14.1.10,Outpatients- Asthma,01-04-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-04-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-04-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-04-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-04-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-04-2024,15,0.00039581
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-04-2024,363,0.009578595
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-04-2024,950,0.025067947
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-04-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-04-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-04-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-04-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-04-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-04-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-04-2024,575,0.015172705
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-04-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-04-2024,18975,0.500699264
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-04-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-04-2024,184,0.004855266
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-04-2024,670,0.0176795
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-04-2024,134,0.0035359
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-04-2024,677,0.017864211
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-04-2024,336,0.008866137
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-04-2024,183,0.004828878
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-04-2024,659,0.017389239
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-04-2024,125,0.003298414
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-04-2024,689,0.018180859
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-04-2024,340,0.008971686
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-04-2024,2,5.28E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-04-2024,1,2.64E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-04-2024,0,0
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-04-2024,3,7.92E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-04-2024,1,2.64E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-04-2024,1,2.64E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-04-2024,14,0.000369422
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-04-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-04-2024,5,0.000131937
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-04-2024,7,0.000184711
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-04-2024,4,0.000105549
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-04-2024,1,2.64E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-04-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-04-2024,0,0
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-04-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-04-2024,308,0.008127292
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-04-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-04-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-04-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-04-2024,19,0.000501359
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-04-2024,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-04-2024,0,0
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-04-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-04-2024,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-04-2024,0,0
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-04-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-04-2024,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-04-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-04-2024,1801,0.047523551
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-04-2024,860,0.022693089
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-04-2024,78,0.00205821
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-04-2024,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-04-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-04-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-04-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-04-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-04-2024,6,0.000158324
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-04-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-04-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-04-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-04-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-04-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-04-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-04-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-04-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-04-2024,417,0.01100351
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-04-2024,11,0.00029026
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-04-2024,294,0.00775787
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-04-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-04-2024,138,0.003641449
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-04-2024,2,5.28E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-04-2024,202,0.005330237
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-04-2024,0,0
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-04-2024,9057,0.238989894
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-04-2024,75,0.001979048
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-04-2024,44,0.001161042
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-04-2024,28,0.000738845
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-04-2024,1,2.64E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-04-2024,2,5.28E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-04-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-04-2024,1,2.64E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-04-2024,5,0.000131937
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-04-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-04-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-04-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-04-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-04-2024,3,7.92E-05
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-04-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-04-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-04-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-04-2024,3,7.92E-05
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-04-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-04-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-04-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-04-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-04-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-04-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-04-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-04-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-04-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-04-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-04-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-04-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-04-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-04-2024,202,0.005330237
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-04-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-04-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-04-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-04-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-04-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-04-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-04-2024,0,0
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-04-2024,0,0
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-04-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-04-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-04-2024,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-04-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-04-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-04-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-04-2024,0,0
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-04-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-04-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-04-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-04-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-04-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-04-2024,242,0.00638573
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-04-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-04-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-04-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-04-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-04-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-04-2024,52033,0.731766658
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-04-2024,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-04-2024,3595,0.050558321
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-04-2024,23,0.000323461
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2024,393,0.00552696
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-04-2024,4,5.63E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-04-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2024,610,0.008578742
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-04-2024,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-04-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-04-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-04-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-04-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-04-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-04-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-04-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-04-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-04-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-04-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-04-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2024,10,0.000140635
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-04-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2024,236,0.003318989
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-04-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-04-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-04-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-04-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-04-2024,78,0.001096954
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-04-2024,2,2.81E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-04-2024,2775,0.039026243
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-04-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-04-2024,1202,0.01690434
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-04-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-04-2024,489,0.006877057
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-04-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-04-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-04-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-04-2024,1090,0.015329227
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-04-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-04-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-04-2024,5,0.161290323
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-04-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-04-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-04-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-04-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-04-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-04-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-04-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-04-2024,208,0.150506512
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-04-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-04-2024,7,0.005065123
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-04-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-04-2024,5,0.003617945
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-04-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-04-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-04-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-04-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-04-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-04-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-04-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-04-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-04-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-04-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-04-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-04-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-04-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-05-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-05-2024,890,0.562223626
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-05-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-05-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-05-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-05-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-05-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-05-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-05-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-05-2024,210,0.132659507
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-05-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-05-2024,13,0.008212255
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-05-2024,13,0.008212255
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-05-2024,185,0.116866709
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-05-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-05-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-05-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-05-2024,480,0.303221731
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-05-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-05-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-05-2024,482,0.304485155
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-05-2024,80,0.050536955
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-05-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-05-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-05-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-05-2024,30,0.018951358
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-05-2024,6,0.003790272
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-05-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-05-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-05-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-05-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-05-2024,181,0.947643979
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-05-2024,96,0.502617801
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-05-2024,60,0.314136126
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-05-2024,181,0.947643979
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-05-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-05-2024,0,0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-05-2024,181,0.947643979
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-05-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-05-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-05-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-05-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-05-2024,85,0.824742268
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-05-2024,25,0.206185567
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-05-2024,85,0.824742268
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-05-2024,87,0.455497382
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-05-2024,94,0.492146597
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-05-2024,12,0.062827225
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-05-2024,10,0.052356021
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-05-2024,181,0.947643979
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-05-2024,35,0.183246073
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-05-2024,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-05-2024,181,0.947643979
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-05-2024,181,0.947643979
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-05-2024,181,0.947643979
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-05-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-05-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-05-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-05-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-05-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-05-2024,181,0.870192308
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-05-2024,181,0.870192308
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-05-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-05-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-05-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-05-2024,13,0.033678756
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-05-2024,5,0.012953368
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-05-2024,14,0.03626943
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-05-2024,1,0.002590674
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-05-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-05-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-05-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-05-2024,6,0.015544041
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-05-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-05-2024,8,0.020725389
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-05-2024,4,0.010362694
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-05-2024,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-05-2024,5,0.012953368
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-05-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-05-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-05-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-05-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-05-2024,100,0.259067358
M8,Family Planning,8.17.1,Complications following male sterilization,01-05-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-05-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-05-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-05-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-05-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-05-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-05-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-05-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-05-2024,181,0.957671958
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-05-2024,181,0.957671958
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-05-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-05-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-05-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-05-2024,181,0.957671958
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-05-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-05-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-05-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-05-2024,181,0.957671958
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-05-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-05-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-05-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-05-2024,22,0.116402116
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-05-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-05-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-05-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-05-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-05-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-05-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-05-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-05-2024,11,0.058201058
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-05-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-05-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-05-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-05-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-05-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-05-2024,4,0.021164021
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-05-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-05-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-05-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-05-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-05-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-05-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-05-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-05-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-05-2024,25,0.132275132
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-05-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-05-2024,118,1
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-05-2024,118,1
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-05-2024,118,1
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-05-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-05-2024,18,0.152542373
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-05-2024,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-05-2024,38,0.322033898
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-05-2024,91,0.342105263
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-05-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-05-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-05-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-05-2024,9,0.033834586
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-05-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-05-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-05-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-05-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-05-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-05-2024,2,0.007518797
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-05-2024,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-05-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-05-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-05-2024,1,0.003759398
M11,NVBDCP,11.4.2,No. of JE positive cases,01-05-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-05-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-05-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-05-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-05-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-05-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-05-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-05-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-05-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-05-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-05-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-05-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-05-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-05-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-05-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-05-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-05-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-05-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-05-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-05-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-05-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-05-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-05-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-05-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-05-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-05-2024,570,0.015040768
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-05-2024,466,0.012296488
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-05-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-05-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-05-2024,614,0.01620181
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-05-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-05-2024,2406,0.063487875
M14,Patient Services,14.1.8,Outpatient - Dental,01-05-2024,1409,0.037179724
M14,Patient Services,14.1.9,Outpatient - ENT ,01-05-2024,1843,0.048631818
M14,Patient Services,14.1.10,Outpatients- Asthma,01-05-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-05-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-05-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-05-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-05-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-05-2024,17,0.000448584
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-05-2024,334,0.008813363
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-05-2024,1850,0.048816529
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-05-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-05-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-05-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-05-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-05-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-05-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-05-2024,707,0.01865583
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-05-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-05-2024,31547,0.832440563
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-05-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-05-2024,192,0.005066364
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-05-2024,874,0.023062512
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-05-2024,184,0.004855266
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-05-2024,895,0.023616645
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-05-2024,461,0.012164551
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-05-2024,187,0.004934428
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-05-2024,814,0.021479273
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-05-2024,163,0.004301132
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-05-2024,838,0.022112568
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-05-2024,429,0.011320157
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-05-2024,2,5.28E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-05-2024,4,0.000105549
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-05-2024,0,0
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-05-2024,2,5.28E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-05-2024,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-05-2024,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-05-2024,9,0.000237486
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-05-2024,1,2.64E-05
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-05-2024,5,0.000131937
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-05-2024,9,0.000237486
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-05-2024,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-05-2024,8,0.000211099
M14,Patient Services,14.3.6,Day Care Admissions,01-05-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-05-2024,0,0
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-05-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-05-2024,357,0.009420271
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-05-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-05-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-05-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-05-2024,25,0.000659683
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-05-2024,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-05-2024,0,0
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-05-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-05-2024,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-05-2024,0,0
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-05-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-05-2024,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-05-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-05-2024,2134,0.056310526
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-05-2024,935,0.024672138
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-05-2024,92,0.002427633
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-05-2024,3,7.92E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-05-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-05-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-05-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-05-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-05-2024,15,0.00039581
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-05-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-05-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-05-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-05-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-05-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-05-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-05-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-05-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-05-2024,604,0.015937937
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-05-2024,19,0.000501359
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-05-2024,362,0.009552207
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-05-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-05-2024,140,0.003694224
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-05-2024,3,7.92E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-05-2024,200,0.005277463
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-05-2024,200,0.005277463
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-05-2024,12413,0.327545716
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-05-2024,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-05-2024,37,0.000976331
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-05-2024,28,0.000738845
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-05-2024,3,7.92E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-05-2024,1,2.64E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-05-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-05-2024,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-05-2024,3,7.92E-05
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-05-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-05-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-05-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-05-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-05-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-05-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-05-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-05-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-05-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-05-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-05-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-05-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-05-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-05-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-05-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-05-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-05-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-05-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-05-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-05-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-05-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-05-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-05-2024,200,0.005277463
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-05-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-05-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-05-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-05-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-05-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-05-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-05-2024,1161,0.03063567
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-05-2024,956,0.025226271
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-05-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-05-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-05-2024,8,0.000211099
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-05-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-05-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-05-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-05-2024,2,5.28E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-05-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-05-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-05-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-05-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-05-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-05-2024,240,0.006332955
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-05-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-05-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-05-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-05-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-05-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-05-2024,61943,0.87113605
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-05-2024,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-05-2024,4512,0.063454561
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-05-2024,25,0.000351588
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2024,469,0.006595787
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-05-2024,3,4.22E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-05-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2024,682,0.009591314
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-05-2024,4,5.63E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-05-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-05-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-05-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-05-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-05-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-05-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-05-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-05-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-05-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-05-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-05-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2024,15,0.000210953
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-05-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2024,262,0.00368464
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-05-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-05-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-05-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-05-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-05-2024,60,0.000843811
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-05-2024,0,0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-05-2024,3062,0.04306247
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-05-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-05-2024,1437,0.020209265
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-05-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-05-2024,541,0.007608359
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-05-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-05-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-05-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-05-2024,989,0.013908812
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-05-2024,5,0.161290323
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-05-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-05-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-05-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-05-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-05-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-05-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-05-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-05-2024,249,0.180173661
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-05-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-05-2024,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-05-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-05-2024,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-05-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-05-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-05-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-05-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-05-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-05-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-05-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-05-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-05-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-05-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-05-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-05-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-05-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-06-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-06-2024,1098,0.693619709
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-06-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-06-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-06-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-06-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-06-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-06-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-06-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-06-2024,50,0.031585597
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-06-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-06-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-06-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-06-2024,42,0.026531901
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-06-2024,25,0.015792798
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-06-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-06-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-06-2024,50,0.031585597
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-06-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-06-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-06-2024,488,0.308275426
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-06-2024,80,0.050536955
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-06-2024,16,0.010107391
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-06-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-06-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-06-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-06-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-06-2024,25,0.015792798
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-06-2024,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-06-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-06-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-06-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-06-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-06-2024,144,0.753926702
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-06-2024,71,0.371727749
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-06-2024,29,0.151832461
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-06-2024,144,0.753926702
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-06-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-06-2024,2,0.010471204
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-06-2024,142,0.743455497
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-06-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-06-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-06-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-06-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-06-2024,73,0.701030928
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-06-2024,21,0.164948454
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-06-2024,73,0.701030928
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-06-2024,74,0.387434555
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-06-2024,66,0.345549738
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-06-2024,22,0.115183246
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-06-2024,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-06-2024,3,0.015706806
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-06-2024,7,0.036649215
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-06-2024,140,0.732984293
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-06-2024,20,0.104712042
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-06-2024,5,0.02617801
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-06-2024,140,0.732984293
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-06-2024,140,0.732984293
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-06-2024,140,0.732984293
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-06-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-06-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-06-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-06-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-06-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-06-2024,140,0.673076923
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-06-2024,140,0.673076923
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-06-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-06-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-06-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-06-2024,6,0.015544041
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-06-2024,1,0.002590674
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-06-2024,9,0.023316062
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-06-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-06-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-06-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-06-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-06-2024,6,0.015544041
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-06-2024,8,0.020725389
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-06-2024,4,0.010362694
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-06-2024,4,0.010362694
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-06-2024,5,0.012953368
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-06-2024,0,0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-06-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-06-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-06-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-06-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-06-2024,67,0.17357513
M8,Family Planning,8.17.1,Complications following male sterilization,01-06-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-06-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-06-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-06-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-06-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-06-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-06-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-06-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-06-2024,140,0.740740741
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-06-2024,140,0.740740741
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-06-2024,44,0.232804233
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-06-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-06-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-06-2024,140,0.740740741
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-06-2024,44,0.232804233
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-06-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-06-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-06-2024,140,0.740740741
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-06-2024,44,0.232804233
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-06-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-06-2024,44,0.232804233
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-06-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-06-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-06-2024,44,0.232804233
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-06-2024,18,0.095238095
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-06-2024,28,0.148148148
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-06-2024,28,0.148148148
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-06-2024,28,0.148148148
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-06-2024,28,0.148148148
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-06-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-06-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-06-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-06-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-06-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-06-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-06-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-06-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-06-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-06-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-06-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-06-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-06-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-06-2024,24,0.203389831
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-06-2024,24,0.203389831
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-06-2024,24,0.203389831
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-06-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-06-2024,6,0.050847458
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-06-2024,2,0.016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-06-2024,24,0.203389831
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-06-2024,115,0.432330827
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-06-2024,1,0.003759398
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-06-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-06-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-06-2024,28,0.105263158
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-06-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-06-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-06-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-06-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-06-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-06-2024,2,0.007518797
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-06-2024,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-06-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-06-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-06-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-06-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-06-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-06-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-06-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-06-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-06-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-06-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-06-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-06-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-06-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-06-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-06-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-06-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-06-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-06-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-06-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-06-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-06-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-06-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-06-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-06-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-06-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-06-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-06-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-06-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-06-2024,525,0.013853339
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-06-2024,450,0.011874291
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-06-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-06-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-06-2024,909,0.023986067
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-06-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-06-2024,2142,0.056521624
M14,Patient Services,14.1.8,Outpatient - Dental,01-06-2024,1156,0.030503734
M14,Patient Services,14.1.9,Outpatient - ENT ,01-06-2024,1780,0.046969417
M14,Patient Services,14.1.10,Outpatients- Asthma,01-06-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-06-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-06-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-06-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-06-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-06-2024,15,0.00039581
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-06-2024,341,0.008998074
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-06-2024,1624,0.042852996
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-06-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-06-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-06-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-06-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-06-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-06-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-06-2024,577,0.01522548
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-06-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-06-2024,33292,0.878486424
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-06-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-06-2024,182,0.004802491
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-06-2024,857,0.022613927
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-06-2024,143,0.003773386
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-06-2024,827,0.021822308
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-06-2024,465,0.012270101
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-06-2024,178,0.004696942
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-06-2024,866,0.022851413
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-06-2024,153,0.004037259
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-06-2024,835,0.022033406
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-06-2024,489,0.012903396
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-06-2024,5,0.000131937
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-06-2024,9,0.000237486
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-06-2024,1,2.64E-05
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-06-2024,7,0.000184711
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-06-2024,5,0.000131937
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-06-2024,3,7.92E-05
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-06-2024,4,0.000105549
M14,Patient Services,14.3.6,Day Care Admissions,01-06-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-06-2024,0,0
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-06-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-06-2024,398,0.010502151
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-06-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-06-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-06-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-06-2024,82,0.00216376
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-06-2024,0,0
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-06-2024,9,0.000237486
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-06-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-06-2024,6,0.000158324
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-06-2024,24,0.000633296
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-06-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-06-2024,0,0
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-06-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-06-2024,2012,0.053091274
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-06-2024,830,0.02190147
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-06-2024,91,0.002401245
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-06-2024,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-06-2024,2,5.28E-05
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-06-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-06-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-06-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-06-2024,16,0.000422197
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-06-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-06-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-06-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-06-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-06-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-06-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-06-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-06-2024,2,5.28E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-06-2024,558,0.014724121
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-06-2024,12,0.000316648
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-06-2024,325,0.008575877
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-06-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-06-2024,130,0.003430351
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-06-2024,2,5.28E-05
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-06-2024,286,0.007546772
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-06-2024,286,0.007546772
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-06-2024,14371,0.379212075
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-06-2024,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-06-2024,0,0
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-06-2024,0,0
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-06-2024,0,0
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-06-2024,0,0
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-06-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-06-2024,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-06-2024,0,0
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-06-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-06-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-06-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-06-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-06-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-06-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-06-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-06-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-06-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-06-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-06-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-06-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-06-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-06-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-06-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-06-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-06-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-06-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-06-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-06-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-06-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-06-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-06-2024,286,0.007546772
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-06-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-06-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-06-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-06-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-06-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-06-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-06-2024,1203,0.031743938
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-06-2024,1068,0.02818165
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-06-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-06-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-06-2024,14,0.000369422
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-06-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-06-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-06-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-06-2024,3,7.92E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-06-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-06-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-06-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-06-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-06-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-06-2024,240,0.006332955
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-06-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-06-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-06-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-06-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-06-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-06-2024,66280,0.932129497
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-06-2024,200,0.002812702
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-06-2024,6402,0.090034596
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-06-2024,23,0.000323461
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2024,535,0.007523978
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-06-2024,3,4.22E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-06-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2024,585,0.008227154
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-06-2024,3,4.22E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-06-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-06-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-06-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-06-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-06-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-06-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-06-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-06-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-06-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-06-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-06-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2024,8,0.000112508
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-06-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2024,308,0.004331561
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-06-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-06-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-06-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-06-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-06-2024,108,0.001518859
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-06-2024,2,2.81E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-06-2024,2938,0.041318595
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-06-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-06-2024,1365,0.019196692
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-06-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-06-2024,500,0.007031755
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-06-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-06-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-06-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-06-2024,688,0.009675695
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-06-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-06-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-06-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-06-2024,7,0.225806452
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-06-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-06-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-06-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-06-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-06-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-06-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-06-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-06-2024,255,0.184515195
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-06-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-06-2024,7,0.005065123
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-06-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-06-2024,5,0.003617945
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-06-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-06-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-06-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-06-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-06-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-06-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-06-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-06-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-06-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-06-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-06-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-06-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-06-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-07-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-07-2024,1379,0.871130764
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-07-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-07-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-07-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-07-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-07-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-07-2024,40,0.025268478
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-07-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-07-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-07-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-07-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-07-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-07-2024,20,0.012634239
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-07-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-07-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-07-2024,49,0.030953885
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-07-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-07-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-07-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-07-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-07-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-07-2024,15,0.009475679
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-07-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-07-2024,30,0.018951358
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-07-2024,8,0.005053696
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-07-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-07-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-07-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-07-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-07-2024,122,0.638743455
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-07-2024,64,0.335078534
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-07-2024,23,0.120418848
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-07-2024,122,0.638743455
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-07-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-07-2024,2,0.010471204
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-07-2024,120,0.628272251
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-07-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-07-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-07-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-07-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-07-2024,58,0.546391753
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-07-2024,21,0.164948454
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-07-2024,58,0.546391753
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-07-2024,56,0.293193717
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-07-2024,66,0.345549738
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-07-2024,16,0.083769634
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-07-2024,1,0.005235602
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-07-2024,9,0.047120419
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-07-2024,122,0.638743455
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-07-2024,21,0.109947644
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-07-2024,9,0.047120419
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-07-2024,122,0.638743455
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-07-2024,122,0.638743455
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-07-2024,122,0.638743455
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-07-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-07-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-07-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-07-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-07-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-07-2024,122,0.586538462
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-07-2024,122,0.586538462
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-07-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-07-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-07-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-07-2024,3,0.007772021
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-07-2024,1,0.002590674
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-07-2024,8,0.020725389
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-07-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-07-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-07-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-07-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-07-2024,4,0.010362694
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-07-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-07-2024,8,0.020725389
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-07-2024,4,0.010362694
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-07-2024,4,0.010362694
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-07-2024,5,0.012953368
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-07-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-07-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-07-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-07-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-07-2024,90,0.233160622
M8,Family Planning,8.17.1,Complications following male sterilization,01-07-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-07-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-07-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-07-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-07-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-07-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-07-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-07-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-07-2024,122,0.645502646
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-07-2024,122,0.645502646
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-07-2024,34,0.17989418
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-07-2024,122,0.645502646
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-07-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-07-2024,34,0.17989418
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-07-2024,122,0.645502646
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-07-2024,34,0.17989418
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-07-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-07-2024,34,0.17989418
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-07-2024,37,0.195767196
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-07-2024,34,0.17989418
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-07-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-07-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-07-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-07-2024,19,0.100529101
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-07-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-07-2024,14,0.074074074
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-07-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-07-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-07-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-07-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-07-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-07-2024,5,0.026455026
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-07-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-07-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-07-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-07-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-07-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-07-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-07-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-07-2024,28,0.237288136
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-07-2024,28,0.237288136
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-07-2024,28,0.237288136
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-07-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-07-2024,15,0.127118644
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-07-2024,4,0.033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-07-2024,14,0.118644068
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-07-2024,176,0.661654135
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-07-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-07-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-07-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-07-2024,46,0.172932331
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-07-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-07-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-07-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-07-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-07-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-07-2024,2,0.007518797
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-07-2024,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-07-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-07-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-07-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-07-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-07-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-07-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-07-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-07-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-07-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-07-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-07-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-07-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-07-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-07-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-07-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-07-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-07-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-07-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-07-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-07-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-07-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-07-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-07-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-07-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-07-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-07-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-07-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-07-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-07-2024,575,0.015172705
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-07-2024,480,0.01266591
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-07-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-07-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-07-2024,1072,0.0282872
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-07-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-07-2024,2270,0.0598992
M14,Patient Services,14.1.8,Outpatient - Dental,01-07-2024,1469,0.038762963
M14,Patient Services,14.1.9,Outpatient - ENT ,01-07-2024,2072,0.054674512
M14,Patient Services,14.1.10,Outpatients- Asthma,01-07-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-07-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-07-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-07-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-07-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-07-2024,16,0.000422197
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-07-2024,355,0.009367496
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-07-2024,1731,0.045676439
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-07-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-07-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-07-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-07-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-07-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-07-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-07-2024,911,0.024038842
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-07-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-07-2024,36697,0.968335224
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-07-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-07-2024,187,0.004934428
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-07-2024,933,0.024619363
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-07-2024,164,0.004327519
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-07-2024,857,0.022613927
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-07-2024,456,0.012032615
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-07-2024,184,0.004855266
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-07-2024,954,0.025173497
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-07-2024,161,0.004248357
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-07-2024,858,0.022640315
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-07-2024,444,0.011715967
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-07-2024,4,0.000105549
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-07-2024,2,5.28E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-07-2024,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-07-2024,1,2.64E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-07-2024,1,2.64E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-07-2024,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-07-2024,11,0.00029026
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-07-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-07-2024,1,2.64E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-07-2024,9,0.000237486
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-07-2024,0,0
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-07-2024,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-07-2024,4,0.000105549
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-07-2024,30,0.000791619
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-07-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-07-2024,261,0.006887089
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-07-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-07-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-07-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-07-2024,112,0.002955379
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-07-2024,1,2.64E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-07-2024,29,0.000765232
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-07-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-07-2024,0,0
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-07-2024,17,0.000448584
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-07-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-07-2024,130,0.003430351
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-07-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-07-2024,1766,0.046599995
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-07-2024,650,0.017151753
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-07-2024,75,0.001979048
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-07-2024,3,7.92E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-07-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-07-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-07-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-07-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-07-2024,6,0.000158324
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-07-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-07-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-07-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-07-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-07-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-07-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-07-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-07-2024,1,2.64E-05
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-07-2024,532,0.014038051
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-07-2024,12,0.000316648
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-07-2024,344,0.009077236
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-07-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-07-2024,120,0.003166478
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-07-2024,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-07-2024,370,0.009763306
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-07-2024,370,0.009763306
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-07-2024,13952,0.368155791
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-07-2024,56,0.00147769
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-07-2024,28,0.000738845
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-07-2024,23,0.000606908
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-07-2024,2,5.28E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-07-2024,3,7.92E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-07-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-07-2024,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-07-2024,42,0.001108267
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-07-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-07-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-07-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-07-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-07-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-07-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-07-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-07-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-07-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-07-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-07-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-07-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-07-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-07-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-07-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-07-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-07-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-07-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-07-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-07-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-07-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-07-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-07-2024,370,0.009763306
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-07-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-07-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-07-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-07-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-07-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-07-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-07-2024,1139,0.030055149
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-07-2024,985,0.025991503
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-07-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-07-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-07-2024,10,0.000263873
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-07-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-07-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-07-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-07-2024,5,0.000131937
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-07-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-07-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-07-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-07-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-07-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-07-2024,250,0.006596828
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-07-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-07-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-07-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-07-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-07-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-07-2024,71106,1
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-07-2024,0,0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-07-2024,5539,0.077897786
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-07-2024,23,0.000323461
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2024,430,0.00604731
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-07-2024,2,2.81E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-07-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2024,583,0.008199027
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-07-2024,1,1.41E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-07-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-07-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-07-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-07-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-07-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-07-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-07-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-07-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-07-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-07-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-07-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2024,15,0.000210953
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2024,1,1.41E-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-07-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2024,218,0.003065845
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2024,1,1.41E-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-07-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-07-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-07-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-07-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-07-2024,126,0.001772002
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-07-2024,13,0.000182826
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-07-2024,3165,0.044511012
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-07-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-07-2024,1589,0.022346919
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-07-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-07-2024,498,0.007003628
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-07-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-07-2024,0,0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-07-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-07-2024,1527,0.021474981
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-07-2024,11,0.35483871
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-07-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-07-2024,2,0.064516129
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-07-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-07-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-07-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-07-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-07-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-07-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-07-2024,250,0.18089725
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-07-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-07-2024,6,0.004341534
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-07-2024,6,0.004341534
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-07-2024,2,0.001447178
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-07-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-07-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-07-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-07-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-07-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-07-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-07-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-07-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-07-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-07-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-07-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-07-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-07-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-08-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-08-2024,959,0.60581175
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-08-2024,5,0.00315856
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-08-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-08-2024,0,0
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-08-2024,46,0.029058749
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-08-2024,22,0.013897663
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-08-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-08-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-08-2024,19,0.012002527
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-08-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-08-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-08-2024,12,0.007580543
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-08-2024,13,0.008212255
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-08-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-08-2024,3,0.001895136
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-08-2024,6,0.003790272
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-08-2024,16,0.010107391
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-08-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-08-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-08-2024,21,0.013265951
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-08-2024,32,0.020214782
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-08-2024,0,0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-08-2024,0,0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-08-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-08-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-08-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-08-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-08-2024,174,0.910994764
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-08-2024,105,0.54973822
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-08-2024,46,0.240837696
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-08-2024,174,0.910994764
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-08-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-08-2024,4,0.020942408
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-08-2024,170,0.890052356
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-08-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-08-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-08-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-08-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-08-2024,69,0.659793814
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-08-2024,24,0.195876289
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-08-2024,69,0.659793814
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-08-2024,82,0.429319372
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-08-2024,90,0.471204188
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-08-2024,22,0.115183246
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-08-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-08-2024,172,0.90052356
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-08-2024,32,0.167539267
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-08-2024,5,0.02617801
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-08-2024,172,0.90052356
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-08-2024,172,0.90052356
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-08-2024,172,0.90052356
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-08-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-08-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-08-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-08-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-08-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-08-2024,172,0.826923077
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-08-2024,172,0.826923077
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-08-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-08-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-08-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-08-2024,4,0.010362694
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-08-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-08-2024,7,0.018134715
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-08-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-08-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-08-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-08-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-08-2024,2,0.005181347
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-08-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-08-2024,2,0.005181347
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-08-2024,1,0.002590674
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-08-2024,3,0.007772021
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-08-2024,0,0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-08-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-08-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-08-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-08-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-08-2024,66,0.170984456
M8,Family Planning,8.17.1,Complications following male sterilization,01-08-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-08-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-08-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-08-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-08-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-08-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-08-2024,12,0.031088083
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-08-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-08-2024,172,0.91005291
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-08-2024,172,0.91005291
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-08-2024,38,0.201058201
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-08-2024,172,0.91005291
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-08-2024,38,0.201058201
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-08-2024,172,0.91005291
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-08-2024,38,0.201058201
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-08-2024,38,0.201058201
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-08-2024,29,0.153439153
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-08-2024,38,0.201058201
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-08-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-08-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-08-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-08-2024,17,0.08994709
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-08-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-08-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-08-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-08-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-08-2024,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-08-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-08-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-08-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-08-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-08-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-08-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-08-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-08-2024,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-08-2024,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-08-2024,8,0.06779661
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-08-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-08-2024,18,0.152542373
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-08-2024,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-08-2024,8,0.06779661
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-08-2024,251,0.943609023
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-08-2024,1,0.003759398
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-08-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-08-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-08-2024,41,0.154135338
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-08-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-08-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-08-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-08-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-08-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-08-2024,3,0.011278195
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-08-2024,0,0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-08-2024,3,0.011278195
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-08-2024,1,0.003759398
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-08-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-08-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-08-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-08-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-08-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-08-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-08-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-08-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-08-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-08-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-08-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-08-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-08-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-08-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-08-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-08-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-08-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-08-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-08-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-08-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-08-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-08-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-08-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-08-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-08-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-08-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-08-2024,675,0.017811436
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-08-2024,520,0.013721403
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-08-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-08-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-08-2024,809,0.021347336
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-08-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-08-2024,2197,0.057972927
M14,Patient Services,14.1.8,Outpatient - Dental,01-08-2024,1399,0.036915851
M14,Patient Services,14.1.9,Outpatient - ENT ,01-08-2024,1857,0.04900124
M14,Patient Services,14.1.10,Outpatients- Asthma,01-08-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-08-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-08-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-08-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-08-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-08-2024,18,0.000474972
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-08-2024,421,0.011109059
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-08-2024,1550,0.040900335
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-08-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-08-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-08-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-08-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-08-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-08-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-08-2024,657,0.017336465
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-08-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-08-2024,33595,0.88648178
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-08-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-08-2024,239,0.006306568
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-08-2024,934,0.02464575
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-08-2024,202,0.005330237
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-08-2024,957,0.025252659
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-08-2024,428,0.01129377
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-08-2024,234,0.006174631
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-08-2024,952,0.025120722
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-08-2024,212,0.00559411
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-08-2024,976,0.025754017
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-08-2024,433,0.011425707
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-08-2024,2,5.28E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-08-2024,0,0
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-08-2024,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-08-2024,2,5.28E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-08-2024,0,0
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-08-2024,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-08-2024,8,0.000211099
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-08-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-08-2024,3,7.92E-05
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-08-2024,10,0.000263873
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-08-2024,5,0.000131937
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-08-2024,5,0.000131937
M14,Patient Services,14.3.6,Day Care Admissions,01-08-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-08-2024,35,0.000923556
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-08-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-08-2024,264,0.006966251
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-08-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-08-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-08-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-08-2024,170,0.004485843
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-08-2024,1,2.64E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-08-2024,33,0.000870781
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-08-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-08-2024,50,0.001319366
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-08-2024,25,0.000659683
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-08-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-08-2024,90,0.002374858
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-08-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-08-2024,1277,0.033696599
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-08-2024,550,0.014513022
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-08-2024,80,0.002110985
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-08-2024,1,2.64E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-08-2024,1,2.64E-05
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-08-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-08-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-08-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-08-2024,19,0.000501359
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-08-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-08-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-08-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-08-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-08-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-08-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-08-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-08-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-08-2024,492,0.012982558
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-08-2024,13,0.000343035
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-08-2024,298,0.007863419
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-08-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-08-2024,142,0.003746998
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-08-2024,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-08-2024,376,0.00992163
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-08-2024,376,0.00992163
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-08-2024,13383,0.35314141
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-08-2024,0,0
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-08-2024,44,0.001161042
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-08-2024,29,0.000765232
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-08-2024,5,0.000131937
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-08-2024,9,0.000237486
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-08-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-08-2024,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-08-2024,6,0.000158324
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-08-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-08-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-08-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-08-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-08-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-08-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-08-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-08-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-08-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-08-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-08-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-08-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-08-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-08-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-08-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-08-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-08-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-08-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-08-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-08-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-08-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-08-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-08-2024,376,0.00992163
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-08-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-08-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-08-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-08-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-08-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-08-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-08-2024,1118,0.029501016
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-08-2024,994,0.026228989
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-08-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-08-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-08-2024,11,0.00029026
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-08-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-08-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-08-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-08-2024,3,7.92E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-08-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-08-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-08-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-08-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-08-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-08-2024,168,0.004433069
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-08-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-08-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-08-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-08-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-08-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-08-2024,68323,0.960861249
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-08-2024,4,5.63E-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-08-2024,5713,0.080344837
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-08-2024,16,0.000225016
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2024,469,0.006595787
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-08-2024,7,9.84E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-08-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2024,546,0.007678677
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-08-2024,8,0.000112508
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-08-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-08-2024,168,0.00236267
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-08-2024,1,1.41E-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-08-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-08-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-08-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-08-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-08-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-08-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-08-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-08-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2024,20,0.00028127
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2024,1,1.41E-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-08-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2024,276,0.003881529
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2024,1,1.41E-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-08-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-08-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-08-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-08-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-08-2024,174,0.002447051
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-08-2024,13,0.000182826
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-08-2024,3036,0.042696819
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-08-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-08-2024,1477,0.020771805
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-08-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-08-2024,473,0.006652041
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-08-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-08-2024,189,0.002658004
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-08-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-08-2024,967,0.013599415
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-08-2024,6,0.193548387
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-08-2024,5,0.161290323
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-08-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-08-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-08-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-08-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-08-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-08-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-08-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-08-2024,232,0.167872648
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-08-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-08-2024,6,0.004341534
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-08-2024,3,0.002170767
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-08-2024,2,0.001447178
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-08-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-08-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-08-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-08-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-08-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-08-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-08-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-08-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-08-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-08-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-08-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-08-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-08-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-09-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-09-2024,450,0.284270373
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-09-2024,8,0.005053696
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-09-2024,10,0.006317119
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-09-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-09-2024,18,0.011370815
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-09-2024,11,0.006948831
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-09-2024,11,0.006948831
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-09-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-09-2024,19,0.012002527
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-09-2024,19,0.012002527
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-09-2024,19,0.012002527
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-09-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-09-2024,41,0.02590019
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-09-2024,31,0.01958307
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-09-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-09-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-09-2024,70,0.044219836
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-09-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-09-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-09-2024,14,0.008843967
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-09-2024,58,0.036639292
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-09-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-09-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-09-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-09-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-09-2024,53,0.033480733
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-09-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-09-2024,44,0.027795325
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-09-2024,13,0.008212255
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-09-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-09-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-09-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-09-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-09-2024,160,0.837696335
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-09-2024,79,0.413612565
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-09-2024,41,0.214659686
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-09-2024,160,0.837696335
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-09-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-09-2024,16,0.083769634
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-09-2024,144,0.753926702
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-09-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-09-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-09-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-09-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-09-2024,81,0.783505155
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-09-2024,30,0.257731959
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-09-2024,81,0.783505155
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-09-2024,84,0.439790576
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-09-2024,74,0.387434555
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-09-2024,17,0.089005236
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-09-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-09-2024,158,0.827225131
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-09-2024,38,0.19895288
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-09-2024,4,0.020942408
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-09-2024,158,0.827225131
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-09-2024,158,0.827225131
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-09-2024,158,0.827225131
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-09-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-09-2024,5,0.02617801
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-09-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-09-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-09-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-09-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-09-2024,158,0.759615385
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-09-2024,158,0.759615385
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-09-2024,158,0.759615385
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-09-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-09-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-09-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-09-2024,7,0.018134715
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-09-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-09-2024,8,0.020725389
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-09-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-09-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-09-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-09-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-09-2024,0,0
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-09-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-09-2024,0,0
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-09-2024,0,0
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-09-2024,0,0
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-09-2024,0,0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-09-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-09-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-09-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-09-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-09-2024,0,0
M8,Family Planning,8.17.1,Complications following male sterilization,01-09-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-09-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-09-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-09-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-09-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-09-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-09-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-09-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-09-2024,158,0.835978836
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-09-2024,158,0.835978836
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-09-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-09-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-09-2024,31,0.164021164
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-09-2024,158,0.835978836
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-09-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-09-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-09-2024,31,0.164021164
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-09-2024,158,0.835978836
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-09-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-09-2024,31,0.164021164
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-09-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-09-2024,24,0.126984127
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-09-2024,31,0.164021164
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-09-2024,40,0.211640212
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-09-2024,31,0.164021164
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-09-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-09-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-09-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-09-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-09-2024,62,0.328042328
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-09-2024,60,0.317460317
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-09-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-09-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-09-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-09-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-09-2024,6,0.031746032
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-09-2024,0,0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-09-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-09-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-09-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-09-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-09-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-09-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-09-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-09-2024,14,0.118644068
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-09-2024,16,0.13559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-09-2024,1,0.008474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-09-2024,22,0.186440678
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-09-2024,22,0.186440678
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-09-2024,22,0.186440678
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-09-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-09-2024,44,0.372881356
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-09-2024,14,0.118644068
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-09-2024,6,0.050847458
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-09-2024,266,1
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-09-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-09-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-09-2024,1,0.003759398
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-09-2024,46,0.172932331
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-09-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-09-2024,1,0.003759398
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-09-2024,1,0.003759398
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-09-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-09-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-09-2024,66,0.248120301
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-09-2024,10,0.037593985
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-09-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-09-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-09-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-09-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-09-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-09-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-09-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-09-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-09-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-09-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-09-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-09-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-09-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-09-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-09-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-09-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-09-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-09-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-09-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-09-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-09-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-09-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-09-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-09-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-09-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-09-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-09-2024,4,0.4
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-09-2024,4,0.4
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-09-2024,4,0.4
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-09-2024,4,0.4
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-09-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-09-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-09-2024,655,0.01728369
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-09-2024,535,0.014117212
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-09-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-09-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-09-2024,775,0.020450168
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-09-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-09-2024,1966,0.051877457
M14,Patient Services,14.1.8,Outpatient - Dental,01-09-2024,1303,0.034382669
M14,Patient Services,14.1.9,Outpatient - ENT ,01-09-2024,1786,0.047127741
M14,Patient Services,14.1.10,Outpatients- Asthma,01-09-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-09-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-09-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-09-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-09-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-09-2024,19,0.000501359
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-09-2024,467,0.012322875
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-09-2024,175,0.00461778
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-09-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-09-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-09-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-09-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-09-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-09-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-09-2024,657,0.017336465
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-09-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-09-2024,31966,0.843496847
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-09-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-09-2024,236,0.006227406
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-09-2024,1000,0.026387313
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-09-2024,209,0.005514948
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-09-2024,935,0.024672138
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-09-2024,245,0.006464892
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-09-2024,243,0.006412117
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-09-2024,885,0.023352772
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-09-2024,203,0.005356625
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-09-2024,1000,0.026387313
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-09-2024,261,0.006887089
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-09-2024,3,7.92E-05
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-09-2024,1,2.64E-05
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-09-2024,1,2.64E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-09-2024,0,0
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-09-2024,2,5.28E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-09-2024,2,5.28E-05
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-09-2024,13,0.000343035
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-09-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-09-2024,0,0
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-09-2024,10,0.000263873
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-09-2024,6,0.000158324
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-09-2024,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-09-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-09-2024,30,0.000791619
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-09-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-09-2024,314,0.008285616
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-09-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-09-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-09-2024,2,5.28E-05
M14,Patient Services,14.4.2,Inpatient - Dengue,01-09-2024,165,0.004353907
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-09-2024,1,2.64E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-09-2024,44,0.001161042
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-09-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-09-2024,35,0.000923556
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-09-2024,10,0.000263873
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-09-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-09-2024,87,0.002295696
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-09-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-09-2024,1262,0.033300789
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-09-2024,350,0.00923556
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-09-2024,75,0.001979048
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-09-2024,2,5.28E-05
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-09-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-09-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-09-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-09-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-09-2024,12,0.000316648
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-09-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-09-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-09-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-09-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-09-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-09-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-09-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-09-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-09-2024,379,0.010000792
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-09-2024,8,0.000211099
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-09-2024,256,0.006755152
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-09-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-09-2024,144,0.003799773
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-09-2024,5,0.000131937
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-09-2024,366,0.009657757
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-09-2024,366,0.009657757
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-09-2024,12767,0.336886825
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-09-2024,71,0.001873499
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-09-2024,41,0.00108188
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-09-2024,19,0.000501359
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-09-2024,8,0.000211099
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-09-2024,3,7.92E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-09-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-09-2024,2,5.28E-05
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-09-2024,5,0.000131937
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-09-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-09-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-09-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-09-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-09-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-09-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-09-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-09-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-09-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-09-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-09-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-09-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-09-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-09-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-09-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-09-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-09-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-09-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-09-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-09-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-09-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-09-2024,0,0
M14,Patient Services,14.21,Total number of blood units issued in month,01-09-2024,366,0.009657757
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-09-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-09-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-09-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-09-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-09-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-09-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-09-2024,1032,0.027231707
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-09-2024,926,0.024434652
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-09-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-09-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-09-2024,8,0.000211099
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-09-2024,0,0
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-09-2024,0,0
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-09-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-09-2024,5,0.000131937
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-09-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-09-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-09-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-09-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-09-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-09-2024,0,0
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-09-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-09-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-09-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-09-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-09-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-09-2024,66838,0.939976936
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-09-2024,13,0.000182826
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-09-2024,5773,0.081188648
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-09-2024,14,0.000196889
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2024,453,0.00637077
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-09-2024,5,7.03E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-09-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2024,613,0.008620932
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-09-2024,2,2.81E-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-09-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-09-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-09-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-09-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-09-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-09-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-09-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-09-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-09-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-09-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-09-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2024,32,0.000450032
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-09-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2024,266,0.003740894
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2024,1,1.41E-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-09-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-09-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-09-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-09-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-09-2024,165,0.002320479
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-09-2024,1,1.41E-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-09-2024,3223,0.045326695
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-09-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-09-2024,1408,0.019801423
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-09-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-09-2024,475,0.006680168
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-09-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-09-2024,160,0.002250162
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-09-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-09-2024,789,0.01109611
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-09-2024,2,0.064516129
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-09-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-09-2024,1,0.032258065
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-09-2024,7,0.225806452
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-09-2024,3,0.096774194
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-09-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-09-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-09-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-09-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-09-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-09-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-09-2024,264,0.191027496
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-09-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-09-2024,5,0.003617945
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-09-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-09-2024,3,0.002170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-09-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-09-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-09-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-09-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-09-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-09-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-09-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-09-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-09-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-09-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-09-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-09-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-09-2024,0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",01-10-2024,0,0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,01-10-2024,1138,0.718888187
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),01-10-2024,3,0.001895136
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),01-10-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),01-10-2024,7,0.004421984
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,01-10-2024,18,0.011370815
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,01-10-2024,9,0.005685407
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,01-10-2024,14,0.008843967
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,01-10-2024,30,0.018951358
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),01-10-2024,14,0.008843967
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),01-10-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),01-10-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),01-10-2024,14,0.008843967
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,01-10-2024,7,0.004421984
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,01-10-2024,1,0.000631712
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,01-10-2024,2,0.001263424
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,01-10-2024,30,0.018951358
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),01-10-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",01-10-2024,0,0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,01-10-2024,34,0.021478206
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,01-10-2024,78,0.049273531
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,01-10-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,01-10-2024,4,0.002526848
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,01-10-2024,0,0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,01-10-2024,64,0.040429564
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,01-10-2024,9,0.005685407
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,01-10-2024,0,0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),01-10-2024,0,0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,01-10-2024,0,0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,01-10-2024,0,0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),01-10-2024,191,1
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",01-10-2024,86,0.45026178
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",01-10-2024,43,0.22513089
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),01-10-2024,191,1
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",01-10-2024,0,0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",01-10-2024,19,0.09947644
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",01-10-2024,172,0.90052356
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",01-10-2024,0,0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,01-10-2024,0,0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,01-10-2024,0,0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,01-10-2024,0,0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,01-10-2024,102,1
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",01-10-2024,36,0.319587629
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",01-10-2024,99,0.969072165
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,01-10-2024,108,0.565445026
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,01-10-2024,83,0.434554974
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),01-10-2024,19,0.09947644
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,01-10-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,01-10-2024,191,1
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,01-10-2024,46,0.240837696
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",01-10-2024,2,0.010471204
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,01-10-2024,126,0.659685864
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,01-10-2024,191,1
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",01-10-2024,191,1
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,01-10-2024,0,0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",01-10-2024,0,0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,01-10-2024,0,0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",01-10-2024,0,0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,01-10-2024,0,0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,01-10-2024,191,0.918269231
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,01-10-2024,191,0.918269231
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",01-10-2024,0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",01-10-2024,0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,01-10-2024,0,0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,01-10-2024,10,0.025906736
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,01-10-2024,0,0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,01-10-2024,13,0.033678756
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,01-10-2024,0,0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),01-10-2024,0,0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,01-10-2024,0,0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,01-10-2024,0,0
M8,Family Planning,8.6,Number of IUCD Removals ,01-10-2024,0,0
M8,Family Planning,8.7,Number of complications following IUCD Insertion,01-10-2024,0,0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,01-10-2024,2,0.005181347
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,01-10-2024,4,0.010362694
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,01-10-2024,6,0.015544041
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,01-10-2024,2,0.005181347
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,01-10-2024,0,0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,01-10-2024,0,0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,01-10-2024,0,0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,01-10-2024,0,0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,01-10-2024,65,0.168393782
M8,Family Planning,8.17.1,Complications following male sterilization,01-10-2024,0,0
M8,Family Planning,8.17.2,Complications following female sterilization ,01-10-2024,0,0
M8,Family Planning,8.17.3,Failures following male sterilization,01-10-2024,0,0
M8,Family Planning,8.17.4,Failures following female sterilization,01-10-2024,0,0
M8,Family Planning,8.17.5,Deaths following male sterilization,01-10-2024,0,0
M8,Family Planning,8.17.6,Deaths following female sterilization,01-10-2024,0,0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),01-10-2024,0,0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),01-10-2024,0,0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),01-10-2024,189,1
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,01-10-2024,184,0.973544974
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,01-10-2024,43,0.227513228
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,01-10-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,01-10-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),01-10-2024,184,0.973544974
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,01-10-2024,43,0.227513228
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,01-10-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,01-10-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),01-10-2024,184,0.973544974
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),01-10-2024,43,0.227513228
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,01-10-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,01-10-2024,43,0.227513228
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,01-10-2024,27,0.142857143
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,01-10-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,01-10-2024,43,0.227513228
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,01-10-2024,26,0.137566138
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),01-10-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,01-10-2024,21,0.111111111
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,01-10-2024,13,0.068783069
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,01-10-2024,8,0.042328042
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),01-10-2024,15,0.079365079
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,01-10-2024,10,0.052910053
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),01-10-2024,2,0.010582011
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),01-10-2024,0,0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),01-10-2024,0,0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",01-10-2024,0,0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",01-10-2024,0,0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",01-10-2024,0,0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",01-10-2024,0,0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,01-10-2024,0,0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,01-10-2024,20,0.169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,01-10-2024,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,01-10-2024,3,0.025423729
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,01-10-2024,20,0.169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,01-10-2024,20,0.169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,01-10-2024,20,0.169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,01-10-2024,0,0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,01-10-2024,16,0.13559322
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,01-10-2024,10,0.084745763
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,01-10-2024,12,0.101694915
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,01-10-2024,152,0.571428571
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,01-10-2024,0,0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,01-10-2024,0,0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,01-10-2024,0,0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,01-10-2024,28,0.105263158
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,01-10-2024,0,0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,01-10-2024,0,0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,01-10-2024,0,0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,01-10-2024,0,0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,01-10-2024,0,0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-10-2024,45,0.169172932
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-10-2024,20,0.07518797
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,01-10-2024,0,0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,01-10-2024,0,0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),01-10-2024,0,0
M11,NVBDCP,11.4.2,No. of JE positive cases,01-10-2024,0,0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,01-10-2024,0,0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,01-10-2024,0,0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),01-10-2024,0,0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,01-10-2024,0,0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,01-10-2024,0,0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",01-10-2024,0,0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",01-10-2024,0,0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",01-10-2024,0,0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",01-10-2024,0,0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,01-10-2024,0,0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,01-10-2024,0,0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,01-10-2024,0,0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,01-10-2024,0,0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,01-10-2024,0,0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,01-10-2024,0,0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,01-10-2024,0,0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),01-10-2024,0,0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,01-10-2024,0,0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),01-10-2024,0,0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,01-10-2024,0,0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",01-10-2024,0,0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,01-10-2024,0,0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",01-10-2024,0,0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",01-10-2024,0,0
M14,Patient Services,14.1.1,Outpatient - Diabetes,01-10-2024,630,0.016624007
M14,Patient Services,14.1.2,Outpatient - Hypertension,01-10-2024,520,0.013721403
M14,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),01-10-2024,0,0
M14,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,01-10-2024,0,0
M14,Patient Services,14.1.5,Outpatient - Mental illness,01-10-2024,696,0.01836557
M14,Patient Services,14.1.6,Outpatient - Epilepsy,01-10-2024,0,0
M14,Patient Services,14.1.7,Outpatient - Ophthalmic Related,01-10-2024,1885,0.049740085
M14,Patient Services,14.1.8,Outpatient - Dental,01-10-2024,1369,0.036124231
M14,Patient Services,14.1.9,Outpatient - ENT ,01-10-2024,1932,0.050980289
M14,Patient Services,14.1.10,Outpatients- Asthma,01-10-2024,0,0
M14,Patient Services,14.1.11,Outpatient - Oral Cancer,01-10-2024,0,0
M14,Patient Services,14.1.12,Outpatient - Breast Cancer,01-10-2024,0,0
M14,Patient Services,14.1.13,Outpatient - Cervical Cancer,01-10-2024,0,0
M14,Patient Services,14.1.14,Outpatient - Other Cancer,01-10-2024,0,0
M14,Patient Services,14.1.15,Outpatient - COPD,01-10-2024,20,0.000527746
M14,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),01-10-2024,392,0.010343827
M14,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,01-10-2024,1100,0.029026044
M14,Patient Services,14.1.18,Outpatient - Tuberculosis,01-10-2024,0,0
M14,Patient Services,14.1.19,Outpatient - Leprosy Cases,01-10-2024,0,0
M14,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,01-10-2024,0,0
M14,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),01-10-2024,0,0
M14,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,01-10-2024,0,0
M14,Patient Services,14.1.23,Outpatient - Palliative Care,01-10-2024,0,0
M14,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,01-10-2024,690,0.018207246
M14,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,01-10-2024,0,0
M14,Patient Services,14.2.1,Allopathic- Outpatient attendance,01-10-2024,31010,0.818270576
M14,Patient Services,14.2.2,Ayush - Outpatient attendance,01-10-2024,0,0
M14,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,01-10-2024,253,0.00667599
M14,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,01-10-2024,1025,0.027046996
M14,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,01-10-2024,205,0.005409399
M14,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,01-10-2024,1070,0.028234425
M14,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,01-10-2024,384,0.010132728
M14,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,01-10-2024,253,0.00667599
M14,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,01-10-2024,972,0.025648468
M14,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,01-10-2024,202,0.005330237
M14,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,01-10-2024,1015,0.026783123
M14,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,01-10-2024,399,0.010528538
M14,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,01-10-2024,5,0.000131937
M14,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,01-10-2024,4,0.000105549
M14,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,01-10-2024,2,5.28E-05
M14,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,01-10-2024,2,5.28E-05
M14,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,01-10-2024,1,2.64E-05
M14,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,01-10-2024,0,0
M14,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,01-10-2024,9,0.000237486
M14,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,01-10-2024,0,0
M14,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,01-10-2024,5,0.000131937
M14,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,01-10-2024,14,0.000369422
M14,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,01-10-2024,2,5.28E-05
M14,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),01-10-2024,3,7.92E-05
M14,Patient Services,14.3.6,Day Care Admissions,01-10-2024,0,0
M14,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,01-10-2024,25,0.000659683
M14,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,01-10-2024,0,0
M14,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,01-10-2024,341,0.008998074
M14,Patient Services,14.3.9,Total number of postmortem conducted at the facility,01-10-2024,0,0
M14,Patient Services,14.3.10,Total number of telemedicine consultation provided,01-10-2024,0,0
M14,Patient Services,14.4.1,Inpatient - Malaria ,01-10-2024,0,0
M14,Patient Services,14.4.2,Inpatient - Dengue,01-10-2024,60,0.001583239
M14,Patient Services,14.4.3,Inpatient - Typhoid,01-10-2024,1,2.64E-05
M14,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",01-10-2024,41,0.00108188
M14,Patient Services,14.4.5,Inpatient - Tuberculosis,01-10-2024,0,0
M14,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),01-10-2024,28,0.000738845
M14,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,01-10-2024,10,0.000263873
M14,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),01-10-2024,0,0
M14,Patient Services,14.4.9,Inpatient - Operated for Cataract,01-10-2024,94,0.002480407
M14,Patient Services,14.4.10,Inpatient - Pallative Care,01-10-2024,0,0
M14,Patient Services,14.5.1,Patients registered at Emergency Department,01-10-2024,1327,0.035015964
M14,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),01-10-2024,510,0.01345753
M14,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",01-10-2024,110,0.002902604
M14,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",01-10-2024,4,0.000105549
M14,Patient Services,14.6.2.a,Emergency - Burn -Admission,01-10-2024,0,0
M14,Patient Services,14.6.2.b,Emergency - Burn -Deaths,01-10-2024,0,0
M14,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,01-10-2024,0,0
M14,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,01-10-2024,0,0
M14,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,01-10-2024,12,0.000316648
M14,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,01-10-2024,0,0
M14,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,01-10-2024,0,0
M14,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,01-10-2024,0,0
M14,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,01-10-2024,0,0
M14,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,01-10-2024,0,0
M14,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,01-10-2024,0,0
M14,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,01-10-2024,0,0
M14,Patient Services,14.7,Total number of deaths occurring at Emergency Department,01-10-2024,0,0
M14,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),01-10-2024,435,0.011478481
M14,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",01-10-2024,10,0.000263873
M14,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",01-10-2024,296,0.007810645
M14,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,01-10-2024,0,0
M14,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),01-10-2024,143,0.003773386
M14,Patient Services,14.8.3,Number of post operative Surgical Site infection,01-10-2024,4,0.000105549
M14,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),01-10-2024,15,0.00039581
M14,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),01-10-2024,15,0.00039581
M14,Patient Services,14.10.,In-Patient Head Count at midnight,01-10-2024,15032,0.396654089
M14,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),01-10-2024,74,0.001952661
M14,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,01-10-2024,51,0.001345753
M14,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,01-10-2024,23,0.000606908
M14,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,01-10-2024,1,2.64E-05
M14,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,01-10-2024,1,2.64E-05
M14,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,01-10-2024,0,0
M14,Patient Services,14.12.1,Number of deaths occurred at SNCU,01-10-2024,0,0
M14,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,01-10-2024,9,0.000237486
M14,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,01-10-2024,0,0
M14,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,01-10-2024,0,0
M14,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,01-10-2024,0,0
M14,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,01-10-2024,0,0
M14,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,01-10-2024,0,0
M14,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),01-10-2024,0,0
M14,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),01-10-2024,0,0
M14,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,01-10-2024,0,0
M14,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,01-10-2024,0,0
M14,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,01-10-2024,0,0
M14,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,01-10-2024,0,0
M14,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,01-10-2024,0,0
M14,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),01-10-2024,0,0
M14,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,01-10-2024,0,0
M14,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,01-10-2024,0,0
M14,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,01-10-2024,0,0
M14,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,01-10-2024,0,0
M14,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,01-10-2024,0,0
M14,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,01-10-2024,0,0
M14,Patient Services,14.19.a,Stock out rate of essential Drugs,01-10-2024,0,0
M14,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,01-10-2024,0,0
M14,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},01-10-2024,150,0.003958097
M14,Patient Services,14.21,Total number of blood units issued in month,01-10-2024,316,0.008338391
M14,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),01-10-2024,0,0
M14,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,01-10-2024,0,0
M14,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,01-10-2024,0,0
M14,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,01-10-2024,0,0
M14,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,01-10-2024,0,0
M14,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),01-10-2024,0,0
M14,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),01-10-2024,1074,0.028339974
M14,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),01-10-2024,946,0.024962398
M14,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),01-10-2024,0,0
M14,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),01-10-2024,0,0
M14,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),01-10-2024,0,0
M14,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,01-10-2024,7,0.000184711
M14,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,01-10-2024,2,5.28E-05
M14,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),01-10-2024,0,0
M14,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),01-10-2024,2,5.28E-05
M14,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),01-10-2024,0,0
M14,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),01-10-2024,0,0
M14,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,01-10-2024,0,0
M14,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),01-10-2024,0,0
M14,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,01-10-2024,0,0
M14,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,01-10-2024,0,0
M14,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),01-10-2024,0,0
M14,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,01-10-2024,0,0
M14,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,01-10-2024,0,0
M14,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,01-10-2024,0,0
M14,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),01-10-2024,0,0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,01-10-2024,63969,0.899628723
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,01-10-2024,30,0.000421905
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,01-10-2024,4936,0.069417489
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",01-10-2024,22,0.000309397
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2024,415,0.005836357
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",01-10-2024,2,2.81E-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",01-10-2024,0,0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2024,531,0.007467724
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",01-10-2024,0,0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",01-10-2024,0,0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-10-2024,0,0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",01-10-2024,0,0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",01-10-2024,0,0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,01-10-2024,0,0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",01-10-2024,0,0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",01-10-2024,0,0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,01-10-2024,0,0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",01-10-2024,0,0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,01-10-2024,0,0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",01-10-2024,0,0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2024,10,0.000140635
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2024,0,0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",01-10-2024,0,0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2024,317,0.004458133
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2024,0,0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",01-10-2024,0,0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,01-10-2024,0,0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",01-10-2024,0,0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",01-10-2024,0,0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,01-10-2024,97,0.001364161
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,01-10-2024,15,0.000210953
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),01-10-2024,3116,0.0438219
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),01-10-2024,0,0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),01-10-2024,1480,0.020813996
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),01-10-2024,0,0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),01-10-2024,543,0.007636486
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),01-10-2024,0,0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),01-10-2024,243,0.003417433
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),01-10-2024,0,0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),01-10-2024,811,0.011405507
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,01-10-2024,9,0.290322581
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,01-10-2024,4,0.129032258
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,01-10-2024,0,0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,01-10-2024,0,0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,01-10-2024,16,0.011577424
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,01-10-2024,0,0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,01-10-2024,69,0.049927641
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,01-10-2024,0,0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",01-10-2024,399,0.288712012
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,01-10-2024,0,0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,01-10-2024,7,0.005065123
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,01-10-2024,5,0.003617945
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,01-10-2024,7,0.005065123
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,01-10-2024,0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,01-10-2024,0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),01-10-2024,0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,01-10-2024,0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,01-10-2024,0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),01-10-2024,0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,01-10-2024,0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,01-10-2024,0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,01-10-2024,0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,01-10-2024,0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,01-10-2024,0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,01-10-2024,0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,01-10-2024,0,
